Method of diagnosing and treating cervical cancer

Abstract

To perform diagnostic testing or rapid detection of various types of cancer, particularly cervical cancer and precancerous lesions.SOLUTION: Provided is a step of detecting farnesyl pyrophosphate synthetase, neurofibromin I, glyceraldehyde-3-phosphate dehydrogenase, fibronectin type III domain-containing protein 1, eukaryotic translation initiation factor 4A-I, L-lactate dehydrogenase B chain, heterogeneous nuclear ribonucleoprotein A1, polycystic kidney disease 1-like protein 1, heat shock cognate 71-kDa protein, ankyrin-3, Rho23 GTPase-activating protein, cytoskeletal keratin 78 type II, α-3 collagen chain (VI), proteasome subunit beta type-5, heterogeneous nuclear ribonucleoprotein A2 / B1, histone H2B type 1-B, DnaJ subfamily C member 13 homolog, β-enolase, glutathione S-transferase P, glutathione S-transferase Mu 3, or fragments thereof.SELECTED DRAWING: Figure 1

Description

[Technical Field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of priority to MX / a / 2019 / 005940, filed May 21, 2019, the entire contents of which are incorporated herein by reference in their entirety.

[0002] FIELD OF THE INVENTION The present invention relates generally to methods of diagnosing and treating cervical cancer in a subject, and more particularly to biomarkers used in the diagnosis of cervical cancer. [Background technology]

[0003] Background information Cervical cancer (CC) is one of the most common cancers among women worldwide. Risk factors associated with this disease include human papillomavirus (HPV), the microbiome, risky sexual behavior, multiple births, smoking, long-term use of hormonal contraceptives, and environmental factors. Cervical cancer is a slow-growing, progressive disease. Lesions that precede cervical cancer and are considered precursors of the condition are cervical intraepithelial neoplasia. These malignant tumors or lesions can occur up to 10 years before cervical cancer develops.

[0004] Human papillomavirus infection (HPV) causes more than 90% of cases. Other risk factors include smoking, a weak immune system, oral contraceptives, early sexual initiation, and having many sexual partners, but these are less important. Cervical cancer typically develops from precancerous changes over 10 to 20 years. Approximately 90% of cervical cancer cases are squamous cell carcinoma, 10% are adenocarcinoma, and a small number are other types. Diagnosis is typically by cervical screening, followed by a biopsy. Medical imaging is then performed to determine whether the cancer has spread.

[0005] Current methods for diagnosing cervical cancer are invasive. The most common method for diagnosing cervical cancer is smear screening using Papanicolaou staining (i.e., Pap smear). There is a need for non-invasive methods for detecting cervical cancer. Summary of the Invention

[0006] The present invention is based on the pioneering discovery that a collection of biomarkers can be used to diagnose cervical cancer.

[0007] In one embodiment, the present invention provides a method for detecting at least one polypeptide in a sample from a subject, wherein the at least one polypeptide is selected from the group consisting of farnesyl pyrophosphate synthase, neurofibromin I, glyceraldehyde-3 phosphate dehydrogenase, fibronectin domain type III-containing protein 1, eukaryotic translation initiation factor 4A-I, L-lactate dehydrogenase B chain, heterogeneous nuclear ribonucleoprotein A1, polycystic kidney disease 1-like protein 1, heat shock protein cognate 71 kDa, ankyrin-3, Rho23 GTPase-activating protein, cytoskeletal keratin 78 type II, alpha-3 collagen chain (VI), beta subunit of proteasome type 5, heterogeneous nuclear ribonucleoprotein A2 / B1, histone H2B The present invention relates to a method for detecting at least one polypeptide selected from type 1-B, a homolog of DnaJ subfamily C member 13, β-enolase, glutathione S-transferase P, glutathione S-transferase Mu3 or a fragment thereof, or a polypeptide or a fragment thereof having at least about 70% sequence identity to a polypeptide having an amino acid sequence selected from SEQ ID NOs: 1 to 20, and a method for diagnosing cervical cancer based on the detection of at least one polypeptide.

[0008] In one embodiment, the sample is selected from the group consisting of blood, plasma, urine, saliva, sweat, organ biopsy, cerebrospinal fluid (CSF), tears, vaginal fluid, feces, skin, and hair. In a particular embodiment, the sample is a blood sample and the subject is a human.

[0009] In another embodiment, the at least one polypeptide is farnesyl pyrophosphate synthase or a fragment thereof, and at least one polypeptide selected from neurofibromin I, glyceraldehyde-3-phosphate dehydrogenase, fibronectin domain type III-containing protein 1, eukaryotic translation initiation factor 4A-I, L-lactate dehydrogenase B chain, heterogeneous nuclear ribonucleoprotein A1, polycystic kidney disease 1-like protein 1, heat shock protein cognate 71 kDa, ankyrin-3, Rho23 GTPase-activating protein, cytoskeletal keratin 78 type II, alpha-3 collagen chain (VI), beta subunit of proteasome type 5, heterogeneous nuclear ribonucleoprotein A2 / B1, histone H2B type 1-B, homolog of DnaJ subfamily C member 13, beta-enolase, glutathione S-transferase P, glutathione S-transferase Mu3, or a fragment thereof. In an additional embodiment, the at least one polypeptide is a polypeptide having at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO: 1 or a fragment thereof, and at least one polypeptide having at least about 70% sequence identity to a polypeptide having an amino acid sequence selected from SEQ ID NOs: 2-20 and fragments thereof.

[0010] In further embodiments, the detection is by protein microarray, fluorescent detection, flow cytometry, microfluidic device, lateral flow assay, vertical flow assay, or immunoassay. In certain embodiments, the detection is by lateral flow assay. In one embodiment, the method also includes administering a treatment to the subject. In a further embodiment, the treatment is surgery, radiation, chemotherapy, targeted therapy, and / or immunotherapy.

[0011] In another embodiment, the present invention provides a method for detecting at least one polypeptide in a sample from a subject, the method comprising the steps of: detecting at least one polypeptide selected from the group consisting of farnesyl pyrophosphate synthase, neurofibromin 1, glyceraldehyde-3 phosphate dehydrogenase, fibronectin domain type III-containing protein 1, eukaryotic translation initiation factor 4A-I, L-lactate dehydrogenase B chain, heterogeneous nuclear ribonucleoprotein A1, polycystic kidney disease 1-like protein 1, heat shock protein cognate protein 71 kDa, ankyrin-3, Rho23 GTPase-activating protein, cytoskeletal keratin 78 type II, alpha-3 collagen chain (VI), beta subunit of proteasome type 5, heterogeneous nuclear ribonucleoprotein A2 / B1, histone H2B and diagnosing cervical cancer based on the detection of at least one polypeptide selected from the group consisting of type 1-B, a homolog of DnaJ subfamily C member 13, β-enolase, glutathione S-transferase P, glutathione S-transferase Mu3 or a fragment thereof, or a polypeptide or fragment thereof having at least about 70% sequence identity to a polypeptide having an amino acid sequence selected from SEQ ID NOs: 1 to 20.

[0012] In one embodiment, the sample is blood, plasma, urine, saliva, sweat, organ biopsy, cerebrospinal fluid (CSF), tears, vaginal fluid, feces, skin, and hair. In a particular embodiment, the sample is a blood sample and the subject is a human.

[0013] In additional embodiments, the at least one polypeptide is farnesyl pyrophosphate synthase or a fragment thereof, and at least one polypeptide selected from neurofibromin I, glyceraldehyde-3-phosphate dehydrogenase, fibronectin domain type III-containing protein 1, eukaryotic translation initiation factor 4A-I, L-lactate dehydrogenase B chain, heterogeneous nuclear ribonucleoprotein A1, polycystic kidney disease 1-like protein 1, cognate heat shock protein 71 kDa, ankyrin-3, Rho23 GTPase-activating protein, cytoskeletal keratin 78 type II, alpha-3 collagen chain (VI), beta subunit of proteasome type 5, heterogeneous nuclear ribonucleoprotein A2 / B1, histone H2B type 1-B, homolog of DnaJ subfamily C member 13, beta-enolase, glutathione S-transferase P, glutathione S-transferase Mu3, or a fragment thereof. In a further aspect, the at least one polypeptide is a polypeptide having at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO: 1, or a fragment thereof, and at least one polypeptide having at least about 70% sequence identity to a polypeptide having an amino acid sequence selected from SEQ ID NOs: 2-20, or a fragment thereof.

[0014] In another embodiment, the detection is by protein microarray, fluorescent detection, flow cytometry, microfluidic device, lateral flow assay, vertical flow assay, or immunoassay. In a particular embodiment, the detection is by lateral flow assay. In one embodiment, the method also includes administering a treatment to the subject. In a particular embodiment, the treatment is surgery, radiation, chemotherapy, targeted therapy, and / or immunotherapy.

[0015] In an additional embodiment, the present invention provides a method of treating cervical cancer in a subject in need thereof, the method comprising: detecting at least one polypeptide in a sample from the subject, wherein the at least one polypeptide is selected from the group consisting of farnesyl pyrophosphate synthase, neurofibromin 1, glyceraldehyde-3 phosphate dehydrogenase, fibronectin domain type III-containing protein 1, eukaryotic translation initiation factor 4A-I, L-lactate dehydrogenase B chain, heterogeneous nuclear ribonucleoprotein A1, polycystic kidney disease 1-like protein 1, heat shock protein cognate 71 kDa, ankyrin-3, Rho23 GTPase-activating protein, cytoskeletal keratin 78 type II, alpha-3 collagen chain (VI), beta subunit of proteasome type 5, heterogeneous nuclear ribonucleoprotein A2 / B1, histone H2B the polypeptide or fragment thereof having at least about 70% sequence identity to a polypeptide having an amino acid sequence selected from SEQ ID NOs: 1 to 20; diagnosing cervical cancer based on the detection of at least one polypeptide; and administering treatment to the subject. In one embodiment, the sample is a blood sample.

[0016] In additional embodiments, the at least one polypeptide is farnesyl pyrophosphate synthase or a fragment thereof, and at least one polypeptide selected from neurofibromin I, glyceraldehyde-3-phosphate dehydrogenase, fibronectin domain type III-containing protein 1, eukaryotic translation initiation factor 4A-I, L-lactate dehydrogenase B chain, heterogeneous nuclear ribonucleoprotein A1, polycystic kidney disease 1-like protein 1, heat shock protein cognate 71 kDa, ankyrin-3, Rho23 GTPase-activating protein, cytoskeletal keratin 78 type II, alpha-3 collagen chain (VI), beta subunit of proteasome type 5, heterogeneous nuclear ribonucleoprotein A2 / B1, histone H2B type 1-B, homolog of DnaJ subfamily C member 13, beta-enolase, glutathione S-transferase P, glutathione S-transferase Mu3, or a fragment thereof. In a further embodiment, the at least one polypeptide is a polypeptide having at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO: 1, or a fragment thereof, and at least one polypeptide having at least about 70% sequence identity to a polypeptide having an amino acid sequence selected from SEQ ID NOs: 2-20, or a fragment thereof.

[0017] In another aspect, detection is by protein microarray, fluorescent detection, flow cytometry, microfluidic device, lateral flow assay, vertical flow, or immunoassay. In a particular aspect, detection is by lateral flow assay. In a further aspect, the treatment is selected from the group consisting of surgery, radiation, chemotherapy, targeted therapy, and immunotherapy.

[0018] In further embodiments, the chemotherapy is cisplatin, carboplatin, paclitaxel, topotecan, docetaxel, ifosfamide, 5-fluorouracil, irinotecan, gemcitabine, or mitomycin. In certain embodiments, the targeted therapy is bevacizumab and the immunotherapy is pembrolizumab.

[0019] In a further embodiment, the present invention provides a method for detecting at least one polypeptide in a sample from a subject, the method comprising the steps of: detecting at least one polypeptide selected from the group consisting of farnesyl pyrophosphate synthase, neurofibromin I, glyceraldehyde-3 phosphate dehydrogenase, fibronectin domain type III-containing protein 1, eukaryotic translation initiation factor 4A-I, L-lactate dehydrogenase B chain, heterogeneous nuclear ribonucleoprotein A1, polycystic kidney disease 1-like protein 1, heat shock protein cognate 71 kDa, ankyrin-3, Rho23 GTPase-activating protein, cytoskeletal keratin 78 type II, alpha-3 collagen chain (VI), beta subunit of proteasome type 5, heterogeneous nuclear ribonucleoprotein A2 / B1, histone H2B and predicting the response to treatment based on the detection of at least one polypeptide selected from the group consisting of type 1-B, a homolog of DnaJ subfamily C member 13, β-enolase, glutathione S-transferase P, glutathione S-transferase Mu3 or a fragment thereof, or a polypeptide or fragment thereof having at least about 70% sequence identity to a polypeptide having an amino acid sequence selected from SEQ ID NOs: 1 to 20.

[0020] In one embodiment, the at least one polypeptide is farnesyl pyrophosphate synthase or a fragment thereof, and at least one polypeptide selected from neurofibromin I, glyceraldehyde-3-phosphate dehydrogenase, fibronectin domain type III-containing protein 1, eukaryotic translation initiation factor 4A-I, L-lactate dehydrogenase B chain, heterogeneous nuclear ribonucleoprotein A1, polycystic kidney disease 1-like protein 1, heat shock protein cognate 71 kDa, ankyrin-3, Rho23 GTPase-activating protein, cytoskeletal keratin 78 type II, alpha-3 collagen chain (VI), beta subunit of proteasome type 5, heterogeneous nuclear ribonucleoprotein A2 / B1, histone H2B type 1-B, homolog of DnaJ subfamily C member 13, beta-enolase, glutathione S-transferase P, glutathione S-transferase Mu3, or a fragment thereof. In another embodiment, the at least one polypeptide is a polypeptide having at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO: 1, or a fragment thereof, and at least one polypeptide having at least about 70% sequence identity to a polypeptide having an amino acid sequence selected from SEQ ID NOs: 2 to 20, or a fragment thereof.

[0021] In further aspects, detection is by protein microarray, fluorescent detection, flow cytometry, microfluidic devices, lateral flow assays, vertical flow, or immunoassays. In further aspects, detection is by lateral flow assays. In certain aspects, the treatment is surgery, radiation, chemotherapy, targeted therapy, and immunotherapy.

[0022] In another embodiment, the present invention provides a method for detecting at least one polypeptide in a sample from a subject, the method comprising the steps of: detecting at least one polypeptide selected from the group consisting of farnesyl pyrophosphate synthase, neurofibromin I, glyceraldehyde-3 phosphate dehydrogenase, fibronectin domain type III-containing protein 1, eukaryotic translation initiation factor 4A-I, L-lactate dehydrogenase B chain, heterogeneous nuclear ribonucleoprotein A1, polycystic kidney disease 1-like protein 1, heat shock protein cognate 71 kDa, ankyrin-3, Rho23 GTPase-activating protein, cytoskeletal keratin 78 type II, alpha-3 collagen chain (VI), beta subunit of proteasome type 5, heterogeneous nuclear ribonucleoprotein A2 / B1, histone H2B and determining the stage of cervical cancer in the subject based on the detection of at least one polypeptide selected from the group consisting of type 1-B, a homolog of DnaJ subfamily C member 13, β-enolase, glutathione S-transferase P, glutathione S-transferase Mu3 or a fragment thereof, or a polypeptide or fragment thereof having at least about 70% sequence identity to a polypeptide having an amino acid sequence selected from SEQ ID NOs: 1 to 20.

[0023] In one embodiment, the at least one polypeptide is farnesyl pyrophosphate synthase or a fragment thereof, and at least one polypeptide selected from neurofibromin I, glyceraldehyde-3-phosphate dehydrogenase, fibronectin domain type III-containing protein 1, eukaryotic translation initiation factor 4A-I, L-lactate dehydrogenase B chain, heterogeneous nuclear ribonucleoprotein A1, polycystic kidney disease 1-like protein 1, heat shock protein cognate 71 kDa, ankyrin-3, Rho23 GTPase-activating protein, cytoskeletal keratin 78 type II, alpha-3 collagen chain (VI), beta subunit of proteasome type 5, heterogeneous nuclear ribonucleoprotein A2 / B1, histone H2B type 1-B, homolog of DnaJ subfamily C member 13, beta-enolase, glutathione S-transferase P, glutathione S-transferase Mu3, or a fragment thereof. In another embodiment, the at least one polypeptide is a polypeptide having at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO: 1, or a fragment thereof, and at least one polypeptide having at least about 70% sequence identity to a polypeptide having an amino acid sequence selected from SEQ ID NOs: 2 to 20, or a fragment thereof.

[0024] In further embodiments, the detection is by protein microarray, fluorescent detection, flow cytometry, microfluidic device, lateral flow assay, vertical assay, or immunoassay. In certain embodiments, the detection is by lateral flow assay. In further embodiments, the method also includes administering a treatment to the subject. In certain embodiments, the treatment is surgery, radiation, chemotherapy, targeted therapy, or immunotherapy. In one embodiment, the cervical cancer is stage I, stage II, stage III, or stage IV.

[0025] In one embodiment, the present invention provides a kit comprising a sample collection unit, a lateral flow device, and instructions for using the lateral flow device.

[0026] In one embodiment, the lateral flow device is configured to detect and / or label proteins selected from the group consisting of farnesyl pyrophosphate synthase, neurofibromin I, glyceraldehyde-3 phosphate dehydrogenase, fibronectin domain type III-containing protein 1, eukaryotic translation initiation factor 4A-I, L-lactate dehydrogenase B chain, heterogeneous nuclear ribonucleoprotein A1, polycystic kidney disease 1-like protein 1, heat shock protein cognate 71 kDa, ankyrin-3, Rho23 GTPase-activating protein, cytoskeletal keratin 78 type II, alpha-3 collagen chain(VI), beta subunit of proteasome type 5, heterogeneous nuclear ribonucleoprotein A2 / B1, and histone H2B. The present invention detects at least one polypeptide selected from the group consisting of type 1-B, a homolog of DnaJ subfamily C member 13, β-enolase, glutathione S-transferase P, glutathione S-transferase Mu3, or fragments thereof, or a polypeptide or fragment thereof having at least about 70% sequence identity with a polypeptide having an amino acid sequence selected from SEQ ID NOs: 1 to 20.

[0027] In additional embodiments, the at least one polypeptide is farnesyl pyrophosphate synthase or a fragment thereof, and at least one polypeptide selected from neurofibromin I, glyceraldehyde-3-phosphate dehydrogenase, fibronectin domain type III-containing protein 1, eukaryotic translation initiation factor 4A-I, L-lactate dehydrogenase B chain, heterogeneous nuclear ribonucleoprotein A1, polycystic kidney disease 1-like protein 1, heat shock protein cognate 71 kDa, ankyrin-3, Rho23 GTPase-activating protein, cytoskeletal keratin 78 type II, alpha-3 collagen chain (VI), beta subunit of proteasome type 5, heterogeneous nuclear ribonucleoprotein A2 / B1, histone H2B type 1-B, homolog of DnaJ subfamily C member 13, beta-enolase, glutathione S-transferase P, glutathione S-transferase Mu3, or a fragment thereof. In a further aspect, the at least one polypeptide is a polypeptide having at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO: 1, or a fragment thereof, and at least one polypeptide having at least about 70% sequence identity to a polypeptide having an amino acid sequence selected from SEQ ID NOs: 2-20, or a fragment thereof.

[0028] In another embodiment, the lateral flow device detects at least one polypeptide by immunoassay.In one embodiment, the sample collection unit collects a blood sample.

[0029] In a further aspect, the present invention provides the use of the detection of at least one polypeptide for the diagnosis of cervical cancer in a subject in need thereof, wherein said at least one polypeptide is selected from the group consisting of farnesyl pyrophosphate synthase, neurofibromin I, glyceraldehyde-3 phosphate dehydrogenase, fibronectin domain type III containing protein 1, eukaryotic translation initiation factor 4A-I, L-lactate dehydrogenase B chain, heterogeneous nuclear ribonucleoprotein A1, polycystic kidney disease 1-like protein 1, heat shock protein cognate 71 kDa, ankyrin-3, Rho23 GTPase activating protein, cytoskeletal keratin 78 type II, alpha-3 collagen chain (VI), beta subunit of proteasome type 5, heterogeneous nuclear ribonucleoprotein A2 / B1, histone H2B. The polypeptide or fragment thereof is selected from the group consisting of type 1-B, a homolog of DnaJ subfamily C member 13, β-enolase, glutathione S-transferase P, glutathione S-transferase Mu3, or a fragment thereof, or a polypeptide having at least about 70% sequence identity with a polypeptide having an amino acid sequence selected from SEQ ID NOs: 1 to 20.

[0030] In a further embodiment, the at least one polypeptide is detected in a sample from the subject, wherein the sample is a blood sample. In another embodiment, the at least one polypeptide is farnesyl pyrophosphate synthase or a fragment thereof, and at least one polypeptide selected from neurofibromin I, glyceraldehyde-3-phosphate dehydrogenase, fibronectin domain type III-containing protein 1, eukaryotic translation initiation factor 4A-I, L-lactate dehydrogenase B chain, heterogeneous nuclear ribonucleoprotein A1, polycystic kidney disease 1-like protein 1, heat shock protein cognate 71 kDa, ankyrin-3, Rho23 GTPase-activating protein, cytoskeletal keratin 78 type II, alpha-3 collagen chain (VI), beta subunit of proteasome type 5, heterogeneous nuclear ribonucleoprotein A2 / B1, histone H2B type 1-B, homolog of DnaJ subfamily C member 13, beta-enolase, glutathione S-transferase P, glutathione S-transferase Mu3, or a fragment thereof. In one embodiment, the at least one polypeptide is a polypeptide having at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO: 1, or a fragment thereof, and at least one polypeptide having at least about 70% sequence identity to a polypeptide having an amino acid sequence selected from SEQ ID NOs: 2 to 20, or a fragment thereof.

[0031] In other embodiments, detection is by protein microarray, fluorescence detection, flow cytometry, microfluidic device, lateral flow assay, vertical flow, or immunoassay. In certain embodiments, detection is by lateral flow assay. [Brief explanation of the drawings]

[0032] [Figure 1] 1 shows a workflow for obtaining secreted proteins in vivo or ex vivo. [Figure 2] 1 is a graph showing the growth kinetics of cell lines in the presence or absence of fetal bovine serum (FBS). [Figure 3A] 1 shows the analysis of the secretome of a cervical cancer cell line and its negative control. [Figure 3B] The number of total proteins in each cell line, the number of unique proteins, and proteins shared between cell lines are shown. [Figure 3C] Figure 3B is a graphical representation of the data presented in Figure 3B. [Figure 4A] 1 shows a dot plot graph showing label-free quantification (LFQ) of 200 cervical cancer (CC) cell line secretome proteins relative to a negative control. [Figure 4B] 1 is a bar graph depicting the expression profile of a protein of interest. [Figure 4C] 1 is a heatmap showing label-free quantification (LFQ) of 200 CC cell line secretome proteins relative to negative controls. [Figure 5A] 1 shows the workflow for collecting blood and serum samples. [Figure 5B] 1 shows a Western blot analysis of FPS (farnesyl pyrophosphatase) in mouse serum. [Figure 5C] Quantification of the data presented in Figure 5B is shown. [Figure 6A] Validation of a candidate protein (farnesyl pyrophosphate synthase) in the serum of patients with CC is shown. [Figure 6B] 1 shows the levels of farnesyl pyrophosphate synthase protein detected in the serum of control patients. [Figure 6C] Quantification of the data presented in Figures 6A and 6B is illustrated. [Figure 7] Figure 7A shows the validation of a candidate protein (farnesyl pyrophosphate synthase) in precancerous cervical lesions. Figure 7B shows the validation of a candidate protein (ankyrin-3) in precancerous cervical lesions. Figure 7C shows the quantification of the data presented in Figures 7A and 7B. [Figure 8A] 1 shows the detection of farnesyl pyrophosphate synthase in the serum of patients with the precancerous lesion L1 by Western blot. [Figure 8B]1 shows the detection of farnesyl pyrophosphate synthase in the serum of patients with the precancerous lesion L2 by Western blot. [Figure 8C] 1 shows the detection of farnesyl pyrophosphate synthase in the serum of control patients by Western blot. [Figure 8D] 8A-8C illustrate quantification of the data provided in FIGS. [Figure 9A] FIG. 1 shows the detection of ankyrin-3 in the serum of patients with the precancerous lesion L1 by Western blot. [Figure 9B] FIG. 1 shows the detection of ankyrin-3 in the serum of patients with the precancerous lesion L2 by Western blot. [Figure 9C] 1 shows the detection of ankyrin-3 in the serum of control patients by Western blot. [Figure 9D] 9A-9C illustrate quantification of the data provided in FIGS. DETAILED DESCRIPTION OF THE INVENTION

[0033] Detailed Description of the Invention The present invention is based on the pioneering discovery that a collection of biomarkers can be used to diagnose cervical cancer.

[0034] Before the compositions and methods of the present invention are described, it is to be understood that this invention is not limited to the particular compositions, methods, and experimental conditions described, as such compositions, methods, and conditions may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, and the scope of the present invention will be limited only by the appended claims.

[0035] As used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural references unless the context clearly dictates otherwise. Thus, for example, reference to "the method" includes one or more methods, and / or steps, of the type described herein that will become apparent to those skilled in the art upon reading this disclosure, etc.

[0036] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.

[0037] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this invention belongs.In carrying out or testing the present invention, any methods and materials similar or equivalent to those described herein can be used, but it is understood that modifications and variations are within the spirit and scope of this disclosure.Preferred methods and materials will now be described.

[0038] Cervical cancer (CC) is one of the most common cancers among women worldwide. Risk factors associated with this disease include human papillomavirus (HPV), the microbiome, risky sexual behavior, multiple births, smoking, long-term use of hormonal contraceptives, and environmental factors. Cervical cancer is a slow-growing, progressive disease. The lesion that precedes cervical cancer and is considered a precursor to the condition is cervical intraepithelial neoplasia.

[0039] These lesions are generally asymptomatic, making timely detection of the disease difficult, and if not detected by any conventional method, there is a risk of developing into CC. Therefore, diagnosing neoplastic lesions or cancer at an early stage from HPV infection is crucial to ensure that these cases can be addressed and treated in a timely and appropriate manner.

[0040] Currently, the gold standard for diagnosing CC is the Pap test, while the most widely used methods for detecting HPV are PCR and viral genome sequencing. While both methods are international benchmarks, these tests have technical limitations due to the need for highly skilled personnel, facilities, and specialized equipment. Furthermore, they are not readily accessible to all female populations, and sociocultural beliefs often prevent women from undergoing the diagnosis.

[0041] Molecular biomarkers will aid in the detection of cervical cancer using noninvasive methods. These biomarkers, based on patient serum samples, can serve as early-stage detection, prognosis, or treatment follow-up for precancerous lesions and cancer. Therefore, they can reduce the incidence of this disease, which remains a public health problem in many low- and high-income countries.

[0042] For all the above reasons, there is an urgent need to develop new and simpler disease detection methods that are applicable for early detection, specific, sensitive, inexpensive, and easily accessible to the population.

[0043] The methods, compositions, and kits disclosed herein can be used for diagnosing, prognosing, and / or monitoring the status or outcome of cancer in a subject. In some embodiments, diagnosing, predicting, and / or monitoring the status or outcome of cancer comprises determining the malignancy or malignant potential of a cancer or tumor. Alternatively, diagnosing, predicting, and / or monitoring the status or outcome of cancer comprises determining the stage of the cancer. Diagnosing, predicting, and / or monitoring the status or outcome of cancer may comprise determining the tumor grade. Alternatively, diagnosing, predicting, and / or monitoring the status or outcome of cancer comprises assessing the risk of developing cancer. In some embodiments, diagnosing, predicting, and / or monitoring the status or outcome of cancer comprises assessing the risk of cancer recurrence. In some embodiments, diagnosing, predicting, and / or monitoring the status or outcome of cancer may comprise determining the effectiveness of a treatment.

[0044] In one embodiment, the present invention relates to a method for detecting at least one polypeptide in a sample from a subject, wherein the at least one polypeptide is selected from the group consisting of farnesyl pyrophosphate synthase, neurofibromin I, glyceraldehyde-3 phosphate dehydrogenase, fibronectin domain type III-containing protein 1, eukaryotic translation initiation factor 4A-I, L-lactate dehydrogenase B chain, heterogeneous nuclear ribonucleoprotein A1, polycystic kidney disease 1-like protein 1, heat shock protein cognate 71 kDa, ankyrin-3, Rho23 GTPase-activating protein, cytoskeletal keratin 78 type II, alpha-3 collagen chain (VI), beta subunit of proteasome type 5, heterogeneous nuclear ribonucleoprotein A2 / B1, histone H2B The present invention relates to a method for detecting at least one polypeptide selected from type 1-B, a homolog of DnaJ subfamily C member 13, β-enolase, glutathione S-transferase P, glutathione S-transferase Mu3 or a fragment thereof, or a polypeptide or fragment thereof having at least about 70% sequence identity to a polypeptide having an amino acid sequence selected from SEQ ID NOs: 1 to 147, and a method for diagnosing cervical cancer based on the detection of the at least one polypeptide. In one embodiment, the at least one polypeptide is a polypeptide having at least about 70% sequence identity to a polypeptide having an amino acid sequence selected from SEQ ID NOs: 1 to 20, or a fragment thereof.

[0045] As used herein, the terms "detect," "detecting," or "detection" can describe either the general act of finding or identifying a polypeptide, or the specific observation of a polypeptide. Detecting can include determining the presence or absence of a polypeptide. Detecting can include quantifying a polypeptide. For example, detecting can include determining the expression level of a polypeptide. For example, a polypeptide can include at least a portion of a polypeptide disclosed herein.

[0046] The polypeptides or biomarkers of the present invention can be detected by any method and used for specific detection and / or identification of proteins, peptides, fragments thereof, variants thereof, or mutants thereof. Examples of methods for detecting proteins include, but are not limited to, spectroscopic measurements (e.g., high-performance liquid chromatography (HPLC), partition chromatography, normal-phase chromatography, displacement chromatography, reverse-phase chromatography (RPC), size-exclusion chromatography, ion-exchange chromatography, bioaffinity chromatography, aqueous normal-phase chromatography, liquid chromatography-mass spectrometry (LC / MS)), and antibody-dependent or immunoassay-based methods (enzyme-linked immunosorbent assay (ELISA), direct ELISA, sandwich ELISA, competitive ELISA, reverse ELISA, protein immunoprecipitation (direct or indirect), individual protein immunoprecipitation (IP), protein complex immunoprecipitation (Co-IP), chromatin immunoprecipitation (ChIP), RNP immunoprecipitation (RIP), immunoelectrophoresis, Western blot, and protein immunostaining). The polypeptides or biomarkers of the present invention can also be detected using protein microarrays, lateral flow assays, or vertical flow assays. In certain embodiments, the polypeptide or biomarker is detected using a lateral flow assay. Lateral flow assays are typically immunoassays, either sandwich or competitive. Typically, these assays use conjugated gold, carbon, or colored latex nanoparticles. These methods can also be used to perform multiplex assays.

[0047] As used herein, the term "subject" refers to any organism to be screened using the diagnostic methods and treated using the therapeutic methods described herein. Such organisms preferably include, but are not limited to, mammals (e.g., murine, simian, equine, bovine, porcine, canine, feline, etc.), most preferably humans.

[0048] As used herein, the term "diagnosed" refers to signs and symptoms of disease or recognition by genetic analysis, pathological analysis, histological analysis, etc. Specifically, the term refers to the diagnosis or detection of cervical cancer.

[0049] The biomarkers of the present invention perform a variety of functions within the cell.

[0050] Farnesyl pyrophosphate synthase (FPPS), also known as dimethylallyltransferase (DMATT) or farnesyl diphosphate synthase (FDPS), is encoded by the FDPS gene in humans and is an enzyme that catalyzes the conversion of dimethylallyl pyrophosphate (DMAPP) and isopentenyl pyrophosphate (IPP) to farnesyl pyrophosphate (FPP).

[0051] Neurofibromin 1 (NF1) is a human gene located on chromosome 17. NF1 encodes neurofibromin, a GTPase-activating protein that negatively regulates the activity of the RAS / MAPK pathway by accelerating the hydrolysis of Ras-bound GTP. NF1 has a high mutation rate, and mutations in NF1 can alter cell growth control and neurodevelopment, resulting in neurofibromatosis type 1 (NF1, also known as von Recklinghausen syndrome).

[0052] Glyceraldehyde 3-phosphate dehydrogenase (GAPDH or less commonly abbreviated as G3PDH) (EC 1.2.1.12) is an approximately 37 kDa enzyme that catalyzes the sixth step of glycolysis, thus responsible for breaking down glucose for energy and carbon molecules. In addition to this long-established metabolic function, GAPDH has recently been associated with several non-metabolic processes, including transcriptional activation, initiation of apoptosis, vesicle shuttling from the endoplasmic reticulum to the Golgi, and fast axonal or axoplasmic transport.

[0053] Fibronectin type III domain-containing protein 1, also known as fibronectin type III domain-containing protein 1, can be an activator of G protein signaling. Fibronectin type III domain-containing protein 1 is encoded by the FNDC1 gene.

[0054] Eukaryotic translation initiation factor 4A-I is an ATP-dependent RNA helicase. It is a subunit of the eIF4F complex, which is involved in CAP recognition and is required for mRNA binding to the ribosome. In the current model of translation initiation, eIF4A unravels the RNA secondary structure in the 5'-UTR of the mRNA. This is necessary to allow efficient binding of the small ribosomal subunit and subsequent scanning of the initiation codon. The protein is encoded by the EIF4A1 gene.

[0055] L-lactate dehydrogenase B chain is involved in step 1 of the subpathway that synthesizes (S)-lactate from pyruvate. The protein is encoded by the LDHB gene.

[0056] Heterogeneous nuclear ribonucleoprotein A1, also known as heterogeneous nuclear ribonucleoprotein A1, is involved in packaging pre-mRNA into hnRNP particles, transport of poly(A) mRNA from the nucleus to the cytoplasm, and may regulate splice site selection. It can bind to specific miRNA hairpins. It binds to IRESs, thereby inhibiting the translation of APAF1, an apoptotic protease activating factor. Heterogeneous nuclear ribonucleoprotein A1 is encoded by the HNRNPA1 gene.

[0057] Polycystic kidney disease 1-like protein 1, also known as polycystic kidney disease protein 1-like 1, is a component of the ciliary calcium channel that regulates calcium concentration within the primary cilium without affecting cytosolic calcium concentration. It heterodimerizes with PKD2L1 in the primary cilium to form a calcium-permeable ciliary channel that regulates Sonic hedgehog / SHH signaling and GLI2 transcription. It does not constitute a pore-forming subunit. It is also involved in left-right axis determination downstream of nodal flow, forming a complex with PKD2 within the cilium to facilitate flow detection during left-right patterning. It is encoded by the PKD1L1 gene.

[0058] The heat shock protein cognate 71 kDa is a molecular chaperone involved in a wide variety of cellular processes, including protecting the proteome from stress, folding and transporting newly synthesized polypeptides, activating proteolysis of misfolded proteins, and forming and dissociating protein complexes. It plays a key role in the protein quality control system, ensuring the correct folding of proteins, refolding misfolded proteins, and targeting proteins for subsequent degradation. This is achieved through cycles of ATP binding, ATP hydrolysis, and ADP release mediated by cochaperones. Cochaperones not only regulate different steps in the HSP70 ATPase cycle, but they have also been shown to have individual specificities, with one cochaperone promoting substrate folding while another may promote degradation. The affinity of HSP70 for polypeptides is regulated by its nucleotide-bound state. In its ATP-bound form, it has low affinity for substrate proteins. However, upon hydrolysis of ATP to ADP, it undergoes a conformational change that increases its affinity for substrate proteins. HSP70 undergoes cycles of ATP hydrolysis and nucleotide exchange to enable cycles of substrate binding and release. There are three types of HSP70-associated cochaperones: the J-domain cochaperone HSP40 (which stimulates ATPase hydrolysis by HSP70), nucleotide exchange factors (NEFs) (e.g., BAG1 / 2 / 3) that promote the conversion of HSP70 from its ADP-bound state to its ATP-bound state, thereby facilitating substrate release), and TPR domain chaperones (e.g., HOPX and STUB1). It acts as a repressor of transcriptional activation. It inhibits the activity of the transcriptional coactivator CITED1 in Smad-mediated transcription. It is a component of the PRP19-CDC5L complex, which forms an integral part of the spliceosome and is required for activating pre-mRNA splicing. It may play a scaffolding role in spliceosome assembly, contacting all other components of the core complex. It binds to bacterial lipopolysaccharide (LPS) and mediates LPS-induced inflammatory responses, including TNF secretion by monocytes.It is involved in the endoplasmic reticulum-associated degradation (ERAD) quality control pathway together with the J-domain-containing cochaperone and E3 ligase STUB1. It interacts with the VGF-derived peptide TLQP-21. This protein is encoded by the HSPA8 gene.

[0059] Ankyrin 3 is found in skeletal muscle and is required for the costamere localization of DMD and βDAG1 (by analogy). It is a membrane-cytoskeleton linker. The protein may be involved in the maintenance / targeting of ion channels and cell adhesion molecules at the node of Ranvier and axon initial point. Dietary Mg 2+ Renal Mg levels are increased by regulating the activity of KCNA1 channels. 2+ It contributes to the regulation of resorption. Ankyrin-3 is encoded by the ANK3 gene.

[0060] Rho23 GTPase-activating protein, also known as Rho GTPase-activating protein 23, is part of the RHO family of small GTPases involved in signal transduction through transmembrane receptors; the GDP-bound form is inactive, while the GTP-bound form is active. GTPase-activating proteins such as ARHGAP23 inactivate RHO family proteins by stimulating GTP hydrolysis. Rho GTPase-activating protein 23 is encoded by the ARHGAP23 gene.

[0061] Keratins are the major structural proteins in epithelial cells, forming a cytoplasmic network of 10-12 nm-wide intermediate filaments, forming a scaffold that provides cells with the ability to withstand mechanical and non-mechanical stress. There are two types of cytoskeletal keratins: type I (acidic) and type II (neutral to basic), and microfilament keratin (i.e., cytoskeletal keratin 78 type II, also known as keratin II cytoskeletal 78). Cytoskeletal keratin 78 type II is encoded by the KRT78 gene.

[0062] The α3 collagen chain (VI), also known as collagen α-3(VI) chain, functions as a cell adhesion protein and is encoded by the COL6A3 gene.

[0063] The β subunit of proteasome type 5, also known as proteasome subunit β5 and 20S proteasome subunit β5, is a protein encoded by the PSMB5 gene in humans. This protein is one of 17 essential subunits (α subunits 1-7, constitutive β subunits 1-7, and inducible subunits including β1i, β2i, and β5i) that contribute to the complete assembly of the 20S proteasome complex. In particular, proteasome subunit β5, together with other β subunits, assembles into two heptameric rings, which subsequently assemble into the proteolytic chamber for substrate degradation. This protein contains "chymotrypsin-like" activity and can cleave peptides after large hydrophobic residues. Eukaryotic proteasomes recognize degradable proteins, including damaged proteins (for protein quality control) or key regulatory protein components (for dynamic biological processes). The essential function of the immunoproteasome, a modified proteasome, is the processing of class I MHC peptides. The β subunit of proteasome type 5 is encoded by the PSMB5 gene.

[0064] Heterogeneous nuclear ribonucleoproteins (hnRNPs) associate with nascent pre-mRNAs and package them into hnRNP particles. The positioning of hnRNP particles on nascent hnRNAs is nonrandom and sequence-dependent, condensing and stabilizing the transcripts and minimizing tangles and knots. Packaging plays a role in various processes, including transcription, pre-mRNA processing, RNA export, subcellular location, mRNA translation, and mature mRNA stability. In the nucleus, hnRNP particles are formed with at least 20 different hnRNPs and heterogeneous nuclear RNAs. They are involved in the transport of specific mRNAs to the cytoplasm in oligodendrocytes and neurons. They act by specifically recognizing and binding to the A2RE (21-nucleotide hnRNP A2 response element) or A2RE11 (a derivative, an 11-nucleotide oligonucleotide) sequence motif present in some mRNAs, facilitating their transport to the cytoplasm. They specifically bind to single-stranded telomeric DNA sequences and protect telomeric DNA repeats from endonuclease digestion (by similarity). It also binds to other RNA molecules, such as primary miRNAs (pri-miRNAs). It specifically recognizes and binds to a subset of nuclear m6A-containing pri-miRNAs, thereby acting as a nuclear "reader" of the N6-methyladenosine (m6A) mark. Binding to m6A-containing pri-miRNAs promotes pri-miRNA processing by enhancing DGCR8 binding to pri-miRNA transcripts. It is likely involved in sorting miRNAs into exosomes after sumoylation by binding to m6A-containing pre-miRNAs. It likely acts as a regulator of mRNA splicing efficiency by binding to m6A-containing pre-miRNAs. It also plays a role in activating the innate immune response. Mechanistically, it senses the presence of viral DNA in the nucleus, homodimerizes, and is demethylated by JMJD6. It then translocates to the cytoplasm, where it activates the TBK1-IRF3 pathway, leading to interferon-α / β production. Heterogeneous nuclear ribonucleoprotein A2 / B1 is a protein that in humans is encoded by the HNRNPA2B1 gene.

[0065] Histone H2B 1-B is the core component of the nucleosome, which packs DNA into compact chromatin and limits its accessibility to cellular machinery that requires DNA as a template. Histones thereby play a central role in transcriptional regulation, DNA repair, DNA replication, and chromosome stability. DNA accessibility is regulated through a complex set of post-translational modifications of histones (also known as the histone code) and nucleosome remodeling. Histone H2B 1-B is encoded by the H2BC3 gene.

[0066] The homolog of DnaJ subfamily C member 13, also known as DnaJ homolog subfamily C member 13, is involved in membrane trafficking through early endosomes (e.g., transferrin recycling to early endosomes for recycling endosomal transport, and EGF and EGFR transport from early endosomes to late endosomes for degradation). It is involved in regulating endosomal membrane tubulation and regulates the dynamics of SNX1 on the endosomal membrane. Through its association with WASHC2, it can link the WASH complex to the retromer SNX-BAR subcomplex. DnaJ homolog subfamily member 13 is encoded by the DNAJC13 gene.

[0067] Enolase 3 (ENO3), more commonly known as beta-enolase (ENO-β), is an enzyme encoded by the ENO3 gene in humans. This gene encodes one of three enolase isoenzymes found in mammals. This isoenzyme is found in adult skeletal muscle cells and may play a role in muscle development and regeneration. A switch from alpha-enolase to beta-enolase occurs in muscle tissue during rodent development. Mutations in this gene have been associated with glycogen storage diseases. Alternatively, splice transcript variants encoding different isoforms have been described.

[0068] Glutathione S-transferases (GSTs) are a family of enzymes that play an important role in detoxification by catalyzing the conjugation of many hydrophobic and electrophilic compounds with reduced glutathione. Based on their biochemical, immunological, and structural properties, soluble GSTs are classified into four major classes: α, μ, π, and θ. The glutathione S-transferase π gene (GSTP1) is a polymorphic gene encoding active, functionally distinct GSTP1 variants, which function in xenobiotic metabolism and are thought to play a role in susceptibility to cancer and other diseases. Glutathione S-transferase P is an enzyme encoded by the GSTP1 gene in humans.

[0069] Glutathione S-transferase Mu3 may govern the uptake and detoxification of both endogenous compounds and xenobiotics at the blood-brain barrier. Glutathione S-transferase Mu3 is encoded by the GSTM3 gene.

[0070] Table 1 shows the amino acid sequences of the biomarkers of the present invention and their variants.

[0071] [Table 1] TIFF2025176041000003.tif228170TIFF2025176041000004.tif229170TIFF2025176041000005.tif229170TIFF2025176041000006.tif229170TIFF2025176041000007.tif228170TIFF2025176041000008.tif228170TIFF2025176041000009.tif229170TIFF2025176041000010.tif225170TIFF2025176041000011.tif228170TIFF2025176041000012.tif229170TIFF2025176041000013.tif229170TIFF2025176041000014.tif229170TIFF2025176041000015.tif228170TIFF2025176041000016.tif229170TIFF2025176041000017.tif229170TIFF2025176041000018.tif230170TIFF2025176041000019.tif230170TIFF2025176041000020.tif230170TIFF2025176041000021.tif229170TIFF2025176041000022.tif229170TIFF2025176041000023.tif230170TIFF2025176041000024.tif228170TIFF2025176041000025.tif229170TIFF2025176041000026.tif229170TIFF2025176041000027.tif230170TIFF2025176041000028.tif230170TIFF2025176041000029.tif228170TIFF2025176041000030.tif229170TIFF2025176041000031.tif228170TIFF2025176041000032.tif228170TIFF2025176041000033.tif228170TIFF2025176041000034.tif229170TIFF2025176041000035.tif228170TIFF2025176041000036.tif229170TIFF2025176041000037.tif229170TIFF2025176041000038.tif230170TIFF2025176041000039.tif229170TIFF2025176041000040.tif163170.

[0072] As used herein, the terms "sequence identity" and "sequence homology" can be used interchangeably and refer to the exact amino acid-to-amino acid correspondence of two polypeptide sequences. Typically, techniques for determining sequence identity involve determining the amino acid sequence of a polypeptide and comparing this sequence to a second amino acid sequence. Two or more sequences can be compared by determining their "percent identity" (also referred to as "percent homology"). Percent identity to a reference sequence, which may be a sequence within a longer molecule, can be calculated by dividing the number of exact matches between two optimally aligned sequences by the length of the reference sequence and multiplying by 100. Percent identity can also be determined by comparing sequence information using an advanced BLAST computer program, including, for example, version 2.2.9 available from the National Institutes of Health. The BLAST program is based on the alignment method of Karlin and Altschul, Proc. Natl. Acad. Sci. USA 87:2264-2268 (1990), and is discussed in Altschul, et al., J. Mol. Biol. 215:403-410 (1990), Karlin and Altschul, Proc. Natl. Acad. Sci. USA 90:5873-5877 (1993), and Altschul et al., Nucleic Acids Res. 25:3389-3402 (1997). Briefly, the BLAST program defines identity as the number of identical aligned symbols (i.e., nucleotides or amino acids) divided by the total number of symbols in the shorter of the two sequences. This program can be used to determine percent identity over the entire length of the sequences being compared. Default parameters are provided to optimize searches with short query sequences, for example using the BLASTP program.This program also allows for the use of a SEG filter to mask off segments of the query sequence, as determined by the SEG program of Wootton and Federhen, Computers and Chemistry 17:149-163 (1993). The desired degree of sequence identity ranges from about 80% to 100%, and integer values ​​therebetween. The percent identity between the disclosed and claimed sequences can be at least about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more, or complete (100%) sequence identity. Generally, an exact match indicates 100% identity over the length of the reference sequence. In some cases, references to percent sequence identity refer to sequence identity measured using BLAST (Basic Local Alignment Search Tool). In other cases, ClustalW can be used for multiple sequence alignment. Still other programs for comparing sequences and / or assessing sequence identity include the Needleman-Wunsch algorithm and the Smith-Waterman algorithm (see, e.g., EMBOSS Water aligner). Optimal alignment can be assessed using any suitable parameters of the selected algorithm, including default parameters.

[0073] In one embodiment, the sequence identity is at least about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% (complete) sequence identity (homology). In one aspect, sequence identity exists over a region of at least about 10, 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, 2500, 2600, 2700, 2800, 2900, 3000 or more amino acids, or over the entire length of the polypeptide.

[0074] As used herein, the term "fragment" refers to at least 10 consecutive amino acids of a polypeptide that can be detected using methods known in the art. A fragment can refer to an "active" fragment, which is a portion of a polypeptide necessary for polypeptide function. A fragment can also be an "immunogenic" fragment, which is a portion of a polypeptide that binds to an antibody.

[0075] As used herein, "sample" or "biological sample" is meant to refer to any "biological sample" collected from a subject and represents the content or composition of the sample source considered in its entirety. Samples can be collected and processed directly for analysis or stored under appropriate storage conditions to maintain the quality of the sample until analysis is complete. Ideally, stored samples remain equivalent to freshly collected samples. The source of the sample can be a visceral, venous, arterial, or fluid source. Non-limiting examples of samples include blood, plasma, urine, saliva, sweat, organ biopsy, cerebrospinal fluid (CSF), tears, vaginal fluid, feces, skin, and hair. In one embodiment, the sample is selected from the group consisting of blood, plasma, urine, saliva, sweat, organ biopsy, cerebrospinal fluid (CSF), tears, vaginal fluid, feces, skin, and hair. In a particular embodiment, the sample is a blood sample and the subject is human. Blood samples include whole blood, plasma, and serum.

[0076] At least one protein refers to one or more proteins. In certain embodiments, the at least one polypeptide comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more proteins. In one embodiment, the at least one protein is selected from the group consisting of farnesyl pyrophosphate synthase, neurofibromin I, glyceraldehyde-3-phosphate dehydrogenase, fibronectin domain type III-containing protein 1, eukaryotic translation initiation factor 4A-I, L-lactate dehydrogenase B chain, heterogeneous nuclear ribonucleoprotein A1, polycystic kidney disease 1-like protein 1, heat shock protein cognate 71 kDa, ankyrin-3, Rho23 GTPase-activating protein, cytoskeletal keratin 78 type II, alpha-3 collagen chain (VI), beta subunit of proteasome type 5, heterogeneous nuclear ribonucleoprotein A2 / B1, histone H2B type 1-B, homolog of DnaJ subfamily C member 13, beta-enolase, glutathione S-transferase P, glutathione S-transferase Mu3, or a fragment thereof. In another embodiment, the at least one protein is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70,SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO:101, SEQ ID NO:102, SEQ ID NO:103, SEQ ID NO:104, SEQ ID NO:105, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO: 112, SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:117, SEQ ID NO:118, SEQ ID NO:119, SEQ ID NO:120, SEQ ID NO:121, SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, or a fragment thereof.

[0077] In one embodiment, the at least one protein is selected from the group consisting of farnesyl pyrophosphate synthase, neurofibromin I, glyceraldehyde-3-phosphate dehydrogenase, fibronectin domain type III-containing protein 1, eukaryotic translation initiation factor 4A-I, L-lactate dehydrogenase B chain, heterogeneous nuclear ribonucleoprotein A1, polycystic kidney disease 1-like protein 1, heat shock protein cognate 71 kDa, ankyrin-3, Rho23 GTPase-activating protein, cytoskeletal keratin 78 type II, alpha-3 collagen chain (VI), beta subunit of proteasome type 5, heterogeneous nuclear ribonucleoprotein A2 / B1, histone H2B type 1-B, homolog of DnaJ subfamily C member 13, beta-enolase, glutathione S-transferase P, glutathione S-transferase Mu3, or a combination thereof. In another embodiment, the at least one protein is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86,SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO:101, SEQ ID NO:102, SEQ ID NO:103, SEQ ID NO:104, SEQ ID NO:105, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111, SEQ ID NO:112, SEQ ID NO:113, SEQ ID NO:114, SEQ ID NO:115, SEQ ID NO:116, SEQ ID NO:117, SEQ ID NO:118, SEQ ID NO:11 9, SEQ ID NO:120, SEQ ID NO:121, SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, SEQ ID NO:147, or a combination thereof.

[0078] The biomarkers of the present invention can be used individually or in combination for the diagnosis of cervical cancer. Any combination of the biomarkers listed above and in Table 1 can be used for the diagnosis of cervical cancer.

[0079] In another embodiment, the at least one polypeptide comprises farnesyl pyrophosphate synthase or a fragment thereof, and at least one polypeptide selected from neurofibromin I, glyceraldehyde-3-phosphate dehydrogenase, fibronectin domain type III-containing protein 1, eukaryotic translation initiation factor 4A-I, L-lactate dehydrogenase B chain, heterogeneous nuclear ribonucleoprotein A1, polycystic kidney disease 1-like protein 1, heat shock protein cognate 71 kDa, ankyrin-3, Rho23 GTPase-activating protein, cytoskeletal keratin 78 type II, alpha-3 collagen chain (VI), beta subunit of proteasome type 5, heterogeneous nuclear ribonucleoprotein A2 / B1, histone H2B type 1-B, homolog of DnaJ subfamily C member 13, beta-enolase, glutathione S-transferase P, glutathione S-transferase Mu3, or a fragment thereof. In an additional embodiment, the at least one polypeptide comprises at least one polypeptide selected from a polypeptide having at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO: 1, and a polypeptide having at least about 70% sequence identity to a polypeptide having an amino acid sequence selected from SEQ ID NOs: 2-20, or a fragment thereof.

[0080] In one embodiment, the at least one polypeptide is selected from the group consisting of farnesyl pyrophosphate synthase and neurofibromin I, farnesyl pyrophosphate synthase and glyceraldehyde-3-phosphate dehydrogenase, farnesyl pyrophosphate synthase and fibronectin domain type III-containing protein 1, farnesyl pyrophosphate synthase and eukaryotic translation initiation factor 4A-I, farnesyl pyrophosphate synthase and L-lactate dehydrogenase B chain, farnesyl pyrophosphate synthase and heterogeneous nuclear ribonucleoprotein A1, farnesyl pyrophosphate synthase and polycystic kidney disease protein 1-like 1, farnesyl pyrophosphate synthase and heat shock protein cognate 71 kDa, farnesyl pyrophosphate synthase and ankyrin-3, farnesyl pyrophosphate synthase and Rho23, farnesyl pyrophosphate synthase and Rho23 GTPase-activating protein, farnesyl pyrophosphate synthase and cytoskeletal keratin 78 type II, farnesyl pyrophosphate synthase and collagen chain (VI) α-3, farnesyl pyrophosphate synthase and the β subunit of proteasome type 5, farnesyl pyrophosphate synthase and heterogeneous nuclear ribonucleoprotein A2 / B1, farnesyl pyrophosphate synthase and histone H2B type 1-B, farnesyl pyrophosphate synthase and a homolog of DnaJ subfamily C member 13, farnesyl pyrophosphate synthase and β-enolase, farnesyl pyrophosphate synthase and glutathione S-transferase P, farnesyl pyrophosphate synthase and glutathione S-transferase Mu3, or fragments thereof.

[0081] In another embodiment, at least one polypeptide comprises SEQ ID NO:1 and SEQ ID NO:2, SEQ ID NO:1 and SEQ ID NO:3, SEQ ID NO:1 and SEQ ID NO:4, SEQ ID NO:1 and SEQ ID NO:5, SEQ ID NO:1 and SEQ ID NO:6, SEQ ID NO:1 and SEQ ID NO:7, SEQ ID NO:1 and SEQ ID NO:8, SEQ ID NO:1 and SEQ ID NO:9, SEQ ID NO:1 and SEQ ID NO:10, SEQ ID NO:1 and SEQ ID NO:11, SEQ ID NO:1 and SEQ ID NO:12, SEQ ID NO:1 and SEQ ID NO:13, SEQ ID NO:1 and SEQ ID NO:14, SEQ ID NO:1 and SEQ ID NO:15, SEQ ID NO:1 and SEQ ID NO:16, SEQ ID NO:1 and SEQ ID NO:17, SEQ ID NO:1 and SEQ ID NO:18, SEQ ID NO:1 and SEQ ID NO:19, SEQ ID NO:1 and SEQ ID NO:20, or a fragment thereof.

[0082] In one embodiment, the at least one polypeptide comprises farnesyl pyrophosphate synthase or a fragment thereof, neurofibromin or a fragment thereof, and at least one additional polypeptide selected from the group consisting of glyceraldehyde-3-phosphate dehydrogenase, fibronectin domain type III-containing protein 1, eukaryotic translation initiation factor 4A-I, L-lactate dehydrogenase B chain, heterogeneous nuclear ribonucleoprotein A1, polycystic kidney disease 1-like protein 1, heat shock protein cognate 71 kDa, ankyrin-3, Rho23 GTPase-activating protein, cytoskeletal keratin 78 type II, alpha-3 collagen chain (VI), beta subunit of proteasome type 5, heterogeneous nuclear ribonucleoprotein A2 / B1, histone H2B type 1-B, homolog of DnaJ subfamily C member 13, beta-enolase, glutathione S-transferase P, glutathione S-transferase Mu3, and fragments thereof.

[0083] In another embodiment, the at least one polypeptide comprises farnesyl pyrophosphate synthase or a fragment thereof, glyceraldehyde-3-phosphate dehydrogenase or a fragment thereof, and at least one additional polypeptide selected from the group consisting of neurofibromin, fibronectin domain type III-containing protein 1, eukaryotic translation initiation factor 4A-I, L-lactate dehydrogenase B chain, heterogeneous nuclear ribonucleoprotein A1, polycystic kidney disease protein 1-like 1, heat shock protein cognate 71 kDa, ankyrin-3, Rho23 GTPase-activating protein, cytoskeletal keratin 78 type II, collagen chain (VI) alpha-3, beta subunit of proteasome type 5, heterogeneous nuclear ribonucleoprotein A2 / B1, histone H2B type 1-B, homolog of DnaJ subfamily C member 13, beta-enolase, glutathione S-transferase P, glutathione S-transferase Mu3, and fragments thereof.

[0084] In one embodiment, the at least one polypeptide comprises farnesyl pyrophosphate synthase or a fragment thereof, fibronectin domain type III-containing protein 1 or a fragment thereof, and at least one additional polypeptide selected from the group consisting of neurofibromin, glyceraldehyde-3-phosphate dehydrogenase, eukaryotic translation initiation factor 4A-I, L-lactate dehydrogenase B chain, heterogeneous nuclear ribonucleoprotein A1, polycystic kidney disease protein 1-like 1, heat shock protein cognate 71 kDa, ankyrin-3, Rho23 GTPase-activating protein, cytoskeletal keratin 78 type II, collagen chain (VI) alpha-3, beta subunit of proteasome type 5, heterogeneous nuclear ribonucleoprotein A2 / B1, histone H2B type 1-B, homolog of DnaJ subfamily C member 13, beta-enolase, glutathione S-transferase P, glutathione S-transferase Mu3, and fragments thereof.

[0085] In another embodiment, the at least one polypeptide comprises farnesyl pyrophosphate synthase or a fragment thereof, eukaryotic translation initiation factor 4A-I or a fragment thereof, and at least one additional polypeptide selected from the group consisting of neurofibromin, glyceraldehyde-3-phosphate dehydrogenase, fibronectin domain type III-containing protein 1, L-lactate dehydrogenase B chain, heterogeneous nuclear ribonucleoprotein A1, polycystic kidney disease protein 1-like 1, heat shock protein cognate 71 kDa, ankyrin-3, Rho23 GTPase-activating protein, cytoskeletal keratin 78 type II, collagen chain (VI) alpha-3, beta subunit of proteasome type 5, heterogeneous nuclear ribonucleoprotein A2 / B1, histone H2B type 1-B, homolog of DnaJ subfamily C member 13, beta-enolase, glutathione S-transferase P, glutathione S-transferase Mu3, and fragments thereof.

[0086] In one embodiment, the at least one polypeptide comprises farnesyl pyrophosphate synthase or a fragment thereof, L-lactate dehydrogenase B chain or a fragment thereof, and at least one additional polypeptide selected from the group consisting of neurofibromin, glyceraldehyde-3-phosphate dehydrogenase, fibronectin domain type III-containing protein 1, eukaryotic translation initiation factor 4A-I, heterogeneous nuclear ribonucleoprotein A1, polycystic kidney disease protein 1-like 1, heat shock protein cognate 71 kDa, ankyrin-3, Rho23 GTPase-activating protein, cytoskeletal keratin 78 type II, collagen chain (VI) alpha-3, beta subunit of proteasome type 5, heterogeneous nuclear ribonucleoprotein A2 / B1, histone H2B type 1-B, homolog of DnaJ subfamily C member 13, beta-enolase, glutathione S-transferase P, glutathione S-transferase Mu3, and fragments thereof.

[0087] In another embodiment, the at least one polypeptide comprises farnesyl pyrophosphate synthase or a fragment thereof, heterogeneous nuclear ribonucleoprotein A1 or a fragment thereof, and at least one additional polypeptide selected from the group consisting of neurofibromin, glyceraldehyde-3-phosphate dehydrogenase, fibronectin domain type III-containing protein 1, eukaryotic translation initiation factor 4A-I, L-lactate dehydrogenase B chain, polycystic kidney disease protein 1-like 1, heat shock protein cognate 71 kDa, ankyrin-3, Rho23 GTPase-activating protein, cytoskeletal keratin 78 type II, collagen chain (VI) alpha-3, beta subunit of proteasome type 5, heterogeneous nuclear ribonucleoprotein A2 / B1, histone H2B type 1-B, homolog of DnaJ subfamily C member 13, beta-enolase, glutathione S-transferase P, glutathione S-transferase Mu3, and fragments thereof.

[0088] In one embodiment, the at least one polypeptide comprises farnesyl pyrophosphate synthase or a fragment thereof, polycystic kidney disease protein 1-like 1 or a fragment thereof, and at least one additional polypeptide selected from the group consisting of neurofibromin, glyceraldehyde-3-phosphate dehydrogenase, fibronectin domain type III-containing protein 1, eukaryotic translation initiation factor 4A-I, L-lactate dehydrogenase B chain, heterogeneous nuclear ribonucleoprotein A1, heat shock protein cognate 71 kDa, ankyrin-3, Rho23 GTPase-activating protein, cytoskeletal keratin 78 type II, collagen chain (VI) alpha-3, beta subunit of proteasome type 5, heterogeneous nuclear ribonucleoprotein A2 / B1, histone H2B type 1-B, homolog of DnaJ subfamily C member 13, beta-enolase, glutathione S-transferase P, glutathione S-transferase Mu3, and fragments thereof.

[0089] In another embodiment, the at least one polypeptide comprises farnesyl pyrophosphate synthase or a fragment thereof, heat shock protein cognate 71 kDa or a fragment thereof, and at least one additional polypeptide selected from the group consisting of neurofibromin, glyceraldehyde-3-phosphate dehydrogenase, fibronectin domain type III-containing protein 1, eukaryotic translation initiation factor 4A-I, L-lactate dehydrogenase B chain, heterogeneous nuclear ribonucleoprotein A1, polycystic kidney disease protein 1-like 1, ankyrin-3, Rho23 GTPase-activating protein, cytoskeletal keratin 78 type II, collagen chain (VI) alpha-3, beta subunit of proteasome type 5, heterogeneous nuclear ribonucleoprotein A2 / B1, histone H2B type 1-B, homolog of DnaJ subfamily C member 13, beta-enolase, glutathione S-transferase P, glutathione S-transferase Mu3, and fragments thereof.

[0090] In one embodiment, the at least one polypeptide comprises farnesyl pyrophosphate synthase or a fragment thereof, ankyrin-3 or a fragment thereof, and at least one additional polypeptide selected from the group consisting of neurofibromin, glyceraldehyde-3-phosphate dehydrogenase, fibronectin domain type III-containing protein 1, eukaryotic translation initiation factor 4A-I, L-lactate dehydrogenase B chain, heterogeneous nuclear ribonucleoprotein A1, polycystic kidney disease protein 1-like 1, heat shock protein cognate 71 kDa, Rho23 GTPase-activating protein, cytoskeletal keratin 78 type II, collagen chain (VI) alpha-3, beta subunit of proteasome type 5, heterogeneous nuclear ribonucleoprotein A2 / B1, histone H2B type 1-B, homolog of DnaJ subfamily C member 13, beta-enolase, glutathione S-transferase P, glutathione S-transferase Mu3, and fragments thereof.

[0091] In another embodiment, the at least one polypeptide comprises farnesyl pyrophosphate synthase or a fragment thereof, Rho23 GTPase-activating protein or a fragment thereof, and at least one additional polypeptide selected from the group consisting of neurofibromin, glyceraldehyde-3-phosphate dehydrogenase, fibronectin domain type III-containing protein 1, eukaryotic translation initiation factor 4A-I, L-lactate dehydrogenase B chain, heterogeneous nuclear ribonucleoprotein A1, polycystic kidney disease protein 1-like 1, heat shock protein cognate 71 kDa, ankyrin-3, cytoskeletal keratin 78 type II, collagen chain (VI) alpha-3, beta subunit of proteasome type 5, heterogeneous nuclear ribonucleoprotein A2 / B1, histone H2B type 1-B, homolog of DnaJ subfamily C member 13, beta-enolase, glutathione S-transferase P, glutathione S-transferase Mu3, and fragments thereof.

[0092] In one embodiment, the at least one polypeptide comprises farnesyl pyrophosphate synthase or a fragment thereof, cytoskeletal keratin 78 type II or a fragment thereof, and at least one additional polypeptide selected from the group consisting of neurofibromin, glyceraldehyde-3-phosphate dehydrogenase, fibronectin domain type III-containing protein 1, eukaryotic translation initiation factor 4A-I, L-lactate dehydrogenase B chain, heterogeneous nuclear ribonucleoprotein A1, polycystic kidney disease protein 1-like 1, heat shock protein cognate 71 kDa, ankyrin-3, Rho23 GTPase-activating protein, collagen chain (VI) alpha-3, beta subunit of proteasome type 5, heterogeneous nuclear ribonucleoprotein A2 / B1, histone H2B type 1-B, homolog of DnaJ subfamily C member 13, beta-enolase, glutathione S-transferase P, glutathione S-transferase Mu3, and fragments thereof.

[0093] In another embodiment, the at least one polypeptide comprises farnesyl pyrophosphate synthase or a fragment thereof, collagen chain (VI) alpha-3 or a fragment thereof, and at least one additional polypeptide selected from the group consisting of neurofibromin, glyceraldehyde-3-phosphate dehydrogenase, fibronectin domain type III-containing protein 1, eukaryotic translation initiation factor 4A-I, L-lactate dehydrogenase B chain, heterogeneous nuclear ribonucleoprotein A1, polycystic kidney disease protein 1-like 1, heat shock protein cognate 71 kDa, ankyrin-3, Rho23 GTPase-activating protein, cytoskeletal keratin 78 type II, beta subunit of proteasome type 5, heterogeneous nuclear ribonucleoprotein A2 / B1, histone H2B type 1-B, homolog of DnaJ subfamily C member 13, beta-enolase, glutathione S-transferase P, glutathione S-transferase Mu3, and fragments thereof.

[0094] In one embodiment, the at least one polypeptide comprises farnesyl pyrophosphate synthase or a fragment thereof, the beta subunit of proteasome type 5 or a fragment thereof, and at least one additional polypeptide selected from the group consisting of neurofibromin, glyceraldehyde-3-phosphate dehydrogenase, fibronectin domain type III-containing protein 1, eukaryotic translation initiation factor 4A-I, L-lactate dehydrogenase B chain, heterogeneous nuclear ribonucleoprotein A1, polycystic kidney disease protein 1-like 1, heat shock protein cognate 71 kDa, ankyrin-3, Rho23 GTPase-activating protein, cytoskeletal keratin 78 type II, collagen chain (VI) alpha-3, heterogeneous nuclear ribonucleoprotein A2 / B1, histone H2B type 1-B, a homolog of DnaJ subfamily C member 13, beta-enolase, glutathione S-transferase P, glutathione S-transferase Mu3, and fragments thereof.

[0095] In another embodiment, the at least one polypeptide comprises farnesyl pyrophosphate synthase or a fragment thereof, heterogeneous nuclear ribonucleoprotein A2 / B1 or a fragment thereof, and at least one additional polypeptide selected from the group consisting of neurofibromin, glyceraldehyde-3-phosphate dehydrogenase, fibronectin domain type III-containing protein 1, eukaryotic translation initiation factor 4A-I, L-lactate dehydrogenase B chain, heterogeneous nuclear ribonucleoprotein A1, polycystic kidney disease protein 1-like 1, heat shock protein cognate 71 kDa, ankyrin-3, Rho23 GTPase-activating protein, cytoskeletal keratin 78 type II, collagen chain (VI) alpha-3, beta subunit of proteasome type 5, histone H2B type 1-B, homolog of DnaJ subfamily C member 13, beta-enolase, glutathione S-transferase P, glutathione S-transferase Mu3, and fragments thereof.

[0096] In one embodiment, the at least one polypeptide comprises farnesyl pyrophosphate synthase or a fragment thereof, histone H2B type 1-B or a fragment thereof, and at least one additional polypeptide selected from the group consisting of neurofibromin, glyceraldehyde-3-phosphate dehydrogenase, fibronectin domain type III-containing protein 1, eukaryotic translation initiation factor 4A-I, L-lactate dehydrogenase B chain, heterogeneous nuclear ribonucleoprotein A1, polycystic kidney disease protein 1-like 1, heat shock protein cognate 71 kDa, ankyrin-3, Rho23 GTPase-activating protein, cytoskeletal keratin 78 type II, collagen chain (VI) alpha-3, beta subunit of proteasome type 5, heterogeneous nuclear ribonucleoprotein A2 / B1, a homolog of DnaJ subfamily C member 13, beta-enolase, glutathione S-transferase P, glutathione S-transferase Mu3, and fragments thereof.

[0097] In another embodiment, the at least one polypeptide comprises farnesyl pyrophosphate synthase or a fragment thereof, a homolog of DnaJ subfamily C member 13 or a fragment thereof, and at least one additional polypeptide selected from the group consisting of neurofibromin, glyceraldehyde-3-phosphate dehydrogenase, fibronectin domain type III-containing protein 1, eukaryotic translation initiation factor 4A-I, L-lactate dehydrogenase B chain, heterogeneous nuclear ribonucleoprotein A1, polycystic kidney disease protein 1-like 1, heat shock protein cognate 71 kDa, ankyrin-3, Rho23 GTPase-activating protein, cytoskeletal keratin 78 type II, collagen chain (VI) alpha-3, beta subunit of proteasome type 5, heterogeneous nuclear ribonucleoprotein A2 / B1, histone H2B type 1-B, beta-enolase, glutathione S-transferase P, glutathione S-transferase Mu3, and fragments thereof.

[0098] In one embodiment, the at least one polypeptide comprises farnesyl pyrophosphate synthase or a fragment thereof, beta-enolase or a fragment thereof, and at least one additional polypeptide selected from the group consisting of neurofibromin, glyceraldehyde-3-phosphate dehydrogenase, fibronectin domain type III-containing protein 1, eukaryotic translation initiation factor 4A-I, L-lactate dehydrogenase B chain, heterogeneous nuclear ribonucleoprotein A1, polycystic kidney disease protein 1-like 1, heat shock protein cognate 71 kDa, ankyrin-3, Rho23 GTPase-activating protein, cytoskeletal keratin 78 type II, collagen chain (VI) alpha-3, beta subunit of proteasome type 5, heterogeneous nuclear ribonucleoprotein A2 / B1, histone H2B type 1-B, a homolog of DnaJ subfamily C member 13, glutathione S-transferase P, glutathione S-transferase Mu3, and fragments thereof.

[0099] In another embodiment, the at least one polypeptide comprises farnesyl pyrophosphate synthase or a fragment thereof, glutathione S-transferase P or a fragment thereof, and at least one additional polypeptide selected from the group consisting of neurofibromin, glyceraldehyde-3-phosphate dehydrogenase, fibronectin domain type III-containing protein 1, eukaryotic translation initiation factor 4A-I, L-lactate dehydrogenase B chain, heterogeneous nuclear ribonucleoprotein A1, polycystic kidney disease protein 1-like 1, heat shock protein cognate 71 kDa, ankyrin-3, Rho23 GTPase-activating protein, cytoskeletal keratin 78 type II, collagen chain (VI) alpha-3, beta subunit of proteasome type 5, heterogeneous nuclear ribonucleoprotein A2 / B1, histone H2B type 1-B, a homolog of DnaJ subfamily C member 13, beta-enolase, glutathione S-transferase Mu3, and fragments thereof.

[0100] In one embodiment, the at least one polypeptide comprises farnesyl pyrophosphate synthase or a fragment thereof, glutathione S-transferase Mu3 or a fragment thereof, and at least one additional polypeptide selected from the group consisting of neurofibromin, glyceraldehyde-3-phosphate dehydrogenase, fibronectin domain type III-containing protein 1, eukaryotic translation initiation factor 4A-I, L-lactate dehydrogenase B chain, heterogeneous nuclear ribonucleoprotein A1, polycystic kidney disease protein 1-like 1, heat shock protein cognate 71 kDa, ankyrin-3, Rho23 GTPase-activating protein, cytoskeletal keratin 78 type II, collagen chain (VI) alpha-3, beta subunit of proteasome type 5, heterogeneous nuclear ribonucleoprotein A2 / B1, histone H2B type 1-B, a homolog of DnaJ subfamily C member 13, beta-enolase, glutathione S-transferase P, and fragments thereof.

[0101] In one embodiment, the at least one polypeptide comprises a polypeptide or fragment thereof having at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO: 1, a polypeptide or fragment thereof having at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO: 2, and at least one additional polypeptide or fragment thereof having at least about 70% sequence identity to a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NOs: 3-20.

[0102] In another embodiment, the at least one polypeptide comprises a polypeptide or fragment thereof having at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO: 1, a polypeptide or fragment thereof having at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO: 3, and a polypeptide selected from the group consisting of SEQ ID NOs: 2 and 4-20, and at least one additional polypeptide and fragment thereof having at least about 70% sequence identity to the amino acid sequence.

[0103] In one embodiment, the at least one polypeptide comprises a polypeptide having at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO: 1 or a fragment thereof, a polypeptide having at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO: 4 or a fragment thereof, and a polypeptide selected from the group consisting of SEQ ID NOs: 2-3 and 5-20, and at least one additional polypeptide and fragment thereof having at least about 70% sequence identity to the amino acid sequence.

[0104] In another embodiment, the at least one polypeptide comprises a polypeptide having at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO: 1 or a fragment thereof, a polypeptide having at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO: 5 or a fragment thereof, and a polypeptide selected from the group consisting of SEQ ID NOs: 2-4 and 6-20, and at least one additional polypeptide and fragment thereof having at least about 70% sequence identity to the amino acid sequence.

[0105] In one embodiment, the at least one polypeptide comprises a polypeptide having at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO: 1 or a fragment thereof, a polypeptide having at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO: 6 or a fragment thereof, and a polypeptide selected from the group consisting of SEQ ID NOs: 2-5 and 7-20, and at least one additional polypeptide and fragment thereof having at least about 70% sequence identity to the amino acid sequence.

[0106] In another embodiment, the at least one polypeptide comprises a polypeptide having at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO: 1 or a fragment thereof, a polypeptide having at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO: 7 or a fragment thereof, and a polypeptide selected from the group consisting of SEQ ID NOs: 2-6 and 8-20, and at least one additional polypeptide and fragment thereof having at least about 70% sequence identity to the amino acid sequence.

[0107] In one embodiment, the at least one polypeptide comprises a polypeptide having at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO: 1 or a fragment thereof, a polypeptide having at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO: 8 or a fragment thereof, and a polypeptide selected from the group consisting of SEQ ID NOs: 2-7 and 9-20, and at least one additional polypeptide and fragment thereof having at least about 70% sequence identity to the amino acid sequence.

[0108] In another embodiment, the at least one polypeptide comprises a polypeptide having at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO: 1 or a fragment thereof, a polypeptide having at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO: 9 or a fragment thereof, and a polypeptide selected from the group consisting of SEQ ID NOs: 2-8 and 10-20, and at least one additional polypeptide and fragment thereof having at least about 70% sequence identity to the amino acid sequence.

[0109] In one embodiment, the at least one polypeptide comprises a polypeptide having at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO: 1 or a fragment thereof, a polypeptide having at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO: 10 or a fragment thereof, and a polypeptide selected from the group consisting of SEQ ID NOs: 2-9 and 11-20, and at least one additional polypeptide and fragment thereof having at least about 70% sequence identity to the amino acid sequence.

[0110] In another embodiment, the at least one polypeptide comprises a polypeptide having at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO: 1 or a fragment thereof, a polypeptide having at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO: 11 or a fragment thereof, and a polypeptide selected from the group consisting of SEQ ID NOs: 2-10 and 12-20, and at least one additional polypeptide and fragment thereof having at least about 70% sequence identity to the amino acid sequence.

[0111] In one embodiment, the at least one polypeptide comprises a polypeptide having at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO: 1 or a fragment thereof, a polypeptide having at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO: 12 or a fragment thereof, and a polypeptide selected from the group consisting of SEQ ID NOs: 2-11 and 13-20, and at least one additional polypeptide and fragment thereof having at least about 70% sequence identity to the amino acid sequence.

[0112] In another embodiment, the at least one polypeptide comprises a polypeptide having at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO: 1 or a fragment thereof, a polypeptide having at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO: 13 or a fragment thereof, and a polypeptide selected from the group consisting of SEQ ID NOs: 2-12 and 14-20, and at least one additional polypeptide and fragment thereof having at least about 70% sequence identity to the amino acid sequence.

[0113] In one embodiment, the at least one polypeptide comprises a polypeptide having at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO: 1 or a fragment thereof, a polypeptide having at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO: 14 or a fragment thereof, and a polypeptide selected from the group consisting of SEQ ID NOs: 2-13 and 15-20, and at least one additional polypeptide and fragment thereof having at least about 70% sequence identity to the amino acid sequence.

[0114] In another embodiment, the at least one polypeptide comprises a polypeptide having at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO: 1 or a fragment thereof, a polypeptide having at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO: 15 or a fragment thereof, and a polypeptide selected from the group consisting of SEQ ID NOs: 2-14 and 16-20, and at least one additional polypeptide and fragment thereof having at least about 70% sequence identity to the amino acid sequence.

[0115] In one embodiment, the at least one polypeptide comprises a polypeptide having at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO: 1 or a fragment thereof, a polypeptide having at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO: 16 or a fragment thereof, and a polypeptide selected from the group consisting of SEQ ID NOs: 2-15 and 17-20, and at least one additional polypeptide and fragment thereof having at least about 70% sequence identity to the amino acid sequence.

[0116] In another embodiment, the at least one polypeptide comprises a polypeptide having at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO: 1 or a fragment thereof, a polypeptide having at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO: 17 or a fragment thereof, and a polypeptide selected from the group consisting of SEQ ID NOs: 2-16 and 18-20, and at least one additional polypeptide and fragment thereof having at least about 70% sequence identity to the amino acid sequence.

[0117] In one embodiment, the at least one polypeptide comprises a polypeptide having at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO: 1 or a fragment thereof, a polypeptide having at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO: 18 or a fragment thereof, and a polypeptide selected from the group consisting of SEQ ID NOs: 2-17 and 19-20, and at least one additional polypeptide and fragment thereof having at least about 70% sequence identity to the amino acid sequence.

[0118] In another embodiment, the at least one polypeptide comprises a polypeptide having at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO: 1 or a fragment thereof, a polypeptide having at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO: 19 or a fragment thereof, and a polypeptide selected from the group consisting of SEQ ID NOs: 2-18 and 20, and at least one additional polypeptide and fragment thereof having at least about 70% sequence identity to the amino acid sequence.

[0119] In one embodiment, the at least one polypeptide includes a polypeptide having at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO: 1 or a fragment thereof, a polypeptide having at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO: 20 or a fragment thereof, and a polypeptide selected from the group consisting of SEQ ID NOs: 2-19, and at least one additional polypeptide and fragment thereof having at least about 70% sequence identity to the amino acid sequence.

[0120] In further aspects, detection is by protein microarray, fluorescence detection, flow cytometry, a microfluidic device, a lateral flow assay, a vertical flow assay, or an immunoassay. In particular aspects, detection is by lateral flow.

[0121] In one embodiment, the method also includes administering a treatment to the subject. In a further embodiment, the treatment is surgery, radiation, chemotherapy, targeted therapy, and / or immunotherapy.

[0122] The term "treatment" is used interchangeably herein with the term "therapeutic method" and refers to both 1) curing, delaying, alleviating symptoms, and / or halting progression of a diagnosed pathological condition or disorder, and 2) as well as prophylactic / preventative measures. Individuals in need of treatment can include those already with a particular medical disorder as well as those who may eventually acquire the disorder (i.e., those in need of preventative measures).

[0123] The terms "therapeutically effective amount," "effective dose," "therapeutically effective dose," "effective amount," and the like refer to an amount of a subject compound that elicits the biological or medical response in a tissue, system, animal, or human that is desired by a researcher, veterinarian, physician, or other clinician.

[0124] The terms "administration of" and / or "administering" should be understood to mean providing a therapeutically effective amount of a pharmaceutical composition to a subject in need of treatment. The route of administration can be enteral, topical, or parenteral. Thus, administration routes include, but are not limited to, intradermal, subcutaneous, intravenous, intraperitoneal, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, transdermal, transtracheal, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, and intrasternal, oral, sublingual, buccal, rectal, vaginal, nasal, and ocular administration, as well as injection, inhalation, and spray. As used herein, the phrases "parenteral administration" and "administered parenterally" refer to modes of administration other than enteral and topical administration. Pharmaceutical compositions can be administered in various dosage units depending on the method of administration. Suitable dosage units include, but are not limited to, powders, tablets, pills, capsules, lozenges, suppositories, patches, nasal drops, injections, implantable sustained-release formulations, lipid complexes, and the like.

[0125] The biomarkers and polypeptides disclosed herein are useful for diagnosing cervical cancer. As used herein, the term "diagnosis" refers to any method of detecting or determining that a subject has cervical cancer.

[0126] In another embodiment, the present invention provides a method for detecting at least one polypeptide in a sample from a subject, the method comprising the steps of: detecting at least one polypeptide selected from the group consisting of farnesyl pyrophosphate synthase, neurofibromin 1, glyceraldehyde-3 phosphate dehydrogenase, fibronectin domain type III-containing protein 1, eukaryotic translation initiation factor 4A-I, L-lactate dehydrogenase B chain, heterogeneous nuclear ribonucleoprotein A1, polycystic kidney disease 1-like protein 1, heat shock protein cognate protein 71 kDa, ankyrin-3, Rho23 GTPase-activating protein, cytoskeletal keratin 78 type II, alpha-3 collagen chain (VI), beta subunit of proteasome type 5, heterogeneous nuclear ribonucleoprotein A2 / B1, histone H2B and diagnosing cervical cancer based on the detection of at least one polypeptide selected from the group consisting of type 1-B, a homolog of DnaJ subfamily C member 13, β-enolase, glutathione S-transferase P, glutathione S-transferase Mu3, or a fragment thereof, or a polypeptide or fragment thereof having at least about 70% sequence identity to a polypeptide having an amino acid sequence selected from SEQ ID NOs: 1 to 147. In one embodiment, the at least one polypeptide is a polypeptide having at least about 70% sequence identity to a polypeptide having an amino acid sequence selected from SEQ ID NOs: 1 to 20, or a fragment thereof.

[0127] In one embodiment, the sample is blood, plasma, urine, saliva, sweat, organ biopsy, cerebrospinal fluid (CSF), tears, vaginal fluid, feces, skin, and hair. In a particular embodiment, the sample is a blood sample and the subject is a human.

[0128] In a further embodiment, the at least one polypeptide is farnesyl pyrophosphate synthase or a fragment thereof, and at least one polypeptide selected from neurofibromin I, glyceraldehyde-3-phosphate dehydrogenase, fibronectin domain type III-containing protein 1, eukaryotic translation initiation factor 4A-I, L-lactate dehydrogenase B chain, heterogeneous nuclear ribonucleoprotein A1, polycystic kidney disease 1-like protein 1, cognate heat shock protein 71 kDa, ankyrin-3, Rho23 GTPase-activating protein, cytoskeletal keratin 78 type II, alpha-3 collagen chain (VI), beta subunit of proteasome type 5, heterogeneous nuclear ribonucleoprotein A2 / B1, histone H2B type 1-B, homolog of DnaJ subfamily C member 13, beta-enolase, glutathione S-transferase P, glutathione S-transferase Mu3, or a fragment thereof. In a further aspect, the at least one polypeptide is a polypeptide having at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO: 1, or a fragment thereof, and at least one polypeptide having at least about 70% sequence identity to a polypeptide having an amino acid sequence selected from SEQ ID NOs: 2-20, or a fragment thereof.

[0129] In another embodiment, the detection is by protein microarray, fluorescent detection, flow cytometry, microfluidic device, lateral flow assay, vertical flow assay, or immunoassay. In a particular embodiment, the detection is by lateral flow. In one embodiment, the method also includes administering a treatment to the subject. In a particular embodiment, the treatment is surgery, radiation, chemotherapy, targeted therapy, and / or immunotherapy.

[0130] In some embodiments, diagnosing, predicting, and / or monitoring the state or outcome of cancer can include determining a treatment regimen. Determining a treatment regimen can include administering an anti-cancer therapeutic. Alternatively, determining a treatment for cancer can include modifying the treatment regimen. Modifying the treatment regimen can include increasing, decreasing, or terminating the treatment regimen.

[0131] Treatment options for cervical cancer include surgery, radiation, chemotherapy, targeted therapy, and immunotherapy.

[0132] Surgical treatment for cervical cancer depends on the type and stage of the disease. For precancerous lesions, surgical interventions include ablation and excision. For advanced cervical cancer, surgical interventions include hysterectomy (simple or radical) and trachelectomy.

[0133] Radiation is used to treat cervical cancer and recurrence of cervical cancer. There are two types of radiation typically used to treat cervical cancer: external beam radiation therapy and brachytherapy. External beam radiation therapy (EBRT) aims to deliver x-rays to the cancer from a machine outside the body. The treatment is much like receiving a regular x-ray, but the radiation dose is more intense. When EBRT is used as the primary treatment for cervical cancer, it is usually combined with chemotherapy. Brachytherapy, or internal radiation therapy, places a radiation source in or near the cancer. Brachytherapy is primarily used in addition to EBRT as part of the primary treatment for cervical cancer.

[0134] Chemotherapy is also used to treat cervical cancer, either alone or in combination with other methods.Chemotherapy can include cisplatin, carboplatin, paclitaxel (Taxol), topotecan, docetaxel (Taxotere), ifosfamide (Ifex), 5-fluorouracil (5-FU), irinotecan (Camptosar), gemcitabine (Gemzar) and mitomycin.Targeted therapy for treating cervical cancer includes bevacizumab.Immunotherapy for treating cervical cancer includes pembrolizumab (PD-1 inhibitor).

[0135] In an additional embodiment, the present invention provides a method of treating cervical cancer in a subject in need thereof, the method comprising: detecting at least one polypeptide in a sample from the subject, wherein the at least one polypeptide is selected from the group consisting of farnesyl pyrophosphate synthase, neurofibromin 1, glyceraldehyde-3 phosphate dehydrogenase, fibronectin domain type III-containing protein 1, eukaryotic translation initiation factor 4A-I, L-lactate dehydrogenase B chain, heterogeneous nuclear ribonucleoprotein A1, polycystic kidney disease 1-like protein 1, heat shock protein cognate 71 kDa, ankyrin-3, Rho23 GTPase-activating protein, cytoskeletal keratin 78 type II, alpha-3 collagen chain (VI), beta subunit of proteasome type 5, heterogeneous nuclear ribonucleoprotein A2 / B1, histone H2B The method includes the steps of: diagnosing cervical cancer based on the detection of at least one polypeptide selected from the group consisting of type 1-B, DnaJ subfamily C member 13 homolog, β-enolase, glutathione S-transferase P, glutathione S-transferase Mu3 or a fragment thereof, or a polypeptide or fragment thereof having at least about 70% sequence identity to a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-147; diagnosing cervical cancer based on the detection of at least one polypeptide; and administering treatment to the subject. In one embodiment, the sample is a blood sample. In one embodiment, the at least one polypeptide is a polypeptide having at least about 70% sequence identity to a polypeptide having an amino acid sequence selected from SEQ ID NOs: 1-20 or a fragment thereof.

[0136] In additional embodiments, the at least one polypeptide is farnesyl pyrophosphate synthase, and at least one polypeptide selected from neurofibromin I, glyceraldehyde-3-phosphate dehydrogenase, fibronectin domain type III-containing protein 1, eukaryotic translation initiation factor 4A-I, L-lactate dehydrogenase B chain, heterogeneous nuclear ribonucleoprotein A1, polycystic kidney disease 1-like protein 1, heat shock protein cognate 71 kDa, ankyrin-3, Rho23 GTPase-activating protein, cytoskeletal keratin 78 type II, alpha-3 collagen chain (VI), beta subunit of proteasome type 5, heterogeneous nuclear ribonucleoprotein A2 / B1, histone H2B type 1-B, homolog of DnaJ subfamily C member 13, beta-enolase, glutathione S-transferase P, glutathione S-transferase Mu3, or a fragment thereof. In a further embodiment, the at least one polypeptide is a polypeptide having at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO: 1, or a fragment thereof, and at least one polypeptide having at least about 70% sequence identity to a polypeptide having an amino acid sequence selected from SEQ ID NOs: 2-20, or a fragment thereof.

[0137] In another embodiment, the detection is by protein microarray, fluorescence detection, flow cytometry, microfluidic device, lateral flow assay, or immunoassay. In a specific embodiment, the detection is by lateral flow assay. In a further embodiment, the treatment is selected from the group consisting of surgery, radiation, chemotherapy, targeted therapy, and immunotherapy. In a further embodiment, the chemotherapy is cisplatin, carboplatin, paclitaxel, topotecan, docetaxel, ifosfamide, 5-fluorouracil, irinotecan, gemcitabine, or mitomycin. In a specific embodiment, the targeted therapy is bevacizumab and the immunotherapy is pembrolizumab.

[0138] The biomarkers of the present invention can be used to predict response to treatment of cervical cancer.

[0139] In a further embodiment, the present invention provides a method for detecting at least one polypeptide in a sample from a subject, the method comprising the steps of: detecting at least one polypeptide selected from the group consisting of farnesyl pyrophosphate synthase, neurofibromin I, glyceraldehyde-3 phosphate dehydrogenase, fibronectin domain type III-containing protein 1, eukaryotic translation initiation factor 4A-I, L-lactate dehydrogenase B chain, heterogeneous nuclear ribonucleoprotein A1, polycystic kidney disease 1-like protein 1, heat shock protein cognate 71 kDa, ankyrin-3, Rho23 GTPase-activating protein, cytoskeletal keratin 78 type II, alpha-3 collagen chain (VI), beta subunit of proteasome type 5, heterogeneous nuclear ribonucleoprotein A2 / B1, histone H2B and predicting the response to treatment based on the detection of at least one polypeptide selected from the group consisting of type 1-B, a homolog of DnaJ subfamily C member 13, β-enolase, glutathione S-transferase P, glutathione S-transferase Mu3, or a fragment thereof, or a polypeptide or fragment thereof having at least about 70% sequence identity to a polypeptide having an amino acid sequence selected from SEQ ID NOs: 1 to 147. In one embodiment, the at least one polypeptide is a polypeptide having at least about 70% sequence identity to a polypeptide having an amino acid sequence selected from SEQ ID NOs: 1 to 20, or a fragment thereof.

[0140] In one embodiment, the at least one polypeptide is farnesyl pyrophosphate synthase or a fragment thereof, and at least one polypeptide selected from neurofibromin I, glyceraldehyde-3-phosphate dehydrogenase, fibronectin domain type III-containing protein 1, eukaryotic translation initiation factor 4A-I, L-lactate dehydrogenase B chain, heterogeneous nuclear ribonucleoprotein A1, polycystic kidney disease 1-like protein 1, heat shock protein cognate 71 kDa, ankyrin-3, Rho23 GTPase-activating protein, cytoskeletal keratin 78 type II, alpha-3 collagen chain (VI), beta subunit of proteasome type 5, heterogeneous nuclear ribonucleoprotein A2 / B1, histone H2B type 1-B, homolog of DnaJ subfamily C member 13, beta-enolase, glutathione S-transferase P, glutathione S-transferase Mu3, or a fragment thereof. In another embodiment, the at least one polypeptide is a polypeptide having at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO: 1, or a fragment thereof, and at least one polypeptide having at least about 70% sequence identity to a polypeptide having an amino acid sequence selected from SEQ ID NOs: 2 to 20, or a fragment thereof.

[0141] In further aspects, detection is by protein microarray, fluorescent detection, flow cytometry, microfluidic devices, lateral flow assays, vertical flow, or immunoassays. In further aspects, detection is by lateral flow assays. In certain aspects, the treatment is surgery, radiation, chemotherapy, targeted therapy, and immunotherapy.

[0142] The biomarkers of the present application are useful for determining the stage of cervical cancer. Cervical cancer can be classified on different scales. The Papanicolaou system classifies lesions by severity, from Grade I (corresponding to normal cytology) to Grade V (corresponding to invasive squamous cell carcinoma of the cervix). The Richard classification system classifies cytology results as follows: negative, reactive or unclassifiable atypical squamous epithelium, HPV infection, cervical intraepithelial neoplasia (CIN) Grades I, II, and III, carcinoma in situ, and invasive squamous cell carcinoma of the cervix. Finally, the Bethesda nomenclature classifies cytology results as follows: negative, ASCUS-ASCH, low-grade intraepithelial lesion, high-grade intraepithelial lesion, and invasive squamous cell carcinoma of the cervix.

[0143] The International Federation of Gynecology and Obstetrics (FIGO) staging system is most often used for cancers of the female reproductive tract, including cervical cancer, in which case clinical staging is used and is based on the results of a doctor's physical examination, biopsy, imaging tests, and several other tests (done during cystoscopy and proctoscopy, etc.).

[0144] [Table 2] TIFF2025176041000042.tif185132TIFF2025176041000043.tif124128

[0145] In another embodiment, the present invention provides a method for detecting at least one polypeptide in a sample from a subject, the method comprising the steps of: detecting at least one polypeptide selected from the group consisting of farnesyl pyrophosphate synthase, neurofibromin I, glyceraldehyde-3 phosphate dehydrogenase, fibronectin domain type III-containing protein 1, eukaryotic translation initiation factor 4A-I, L-lactate dehydrogenase B chain, heterogeneous nuclear ribonucleoprotein A1, polycystic kidney disease 1-like protein 1, heat shock protein cognate 71 kDa, ankyrin-3, Rho23 GTPase-activating protein, cytoskeletal keratin 78 type II, alpha-3 collagen chain (VI), beta subunit of proteasome type 5, heterogeneous nuclear ribonucleoprotein A2 / B1, histone H2B and determining the stage of cervical cancer in the subject based on the detection of at least one polypeptide selected from the group consisting of type 1-B, a DnaJ subfamily C member 13 homolog, β-enolase, glutathione S-transferase P, glutathione S-transferase Mu3 or a fragment thereof, or a polypeptide or fragment thereof having at least about 70% sequence identity to a polypeptide having an amino acid sequence selected from SEQ ID NOs: 1 to 147. In one embodiment, the at least one polypeptide is a polypeptide having an amino acid sequence selected from SEQ ID NOs: 1 to 20 or a fragment thereof.

[0146] In one embodiment, the at least one polypeptide is farnesyl pyrophosphate synthase or a fragment thereof, and at least one polypeptide selected from neurofibromin I, glyceraldehyde-3-phosphate dehydrogenase, fibronectin domain type III-containing protein 1, eukaryotic translation initiation factor 4A-I, L-lactate dehydrogenase B chain, heterogeneous nuclear ribonucleoprotein A1, polycystic kidney disease 1-like protein 1, heat shock protein cognate 71 kDa, ankyrin-3, Rho23 GTPase-activating protein, cytoskeletal keratin 78 type II, alpha-3 collagen chain (VI), beta subunit of proteasome type 5, heterogeneous nuclear ribonucleoprotein A2 / B1, histone H2B type 1-B, homolog of DnaJ subfamily C member 13, beta-enolase, glutathione S-transferase P, glutathione S-transferase Mu3, or a fragment thereof. In another embodiment, the at least one polypeptide is a polypeptide having at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO: 1, or a fragment thereof, and at least one polypeptide having at least about 70% sequence identity to a polypeptide having an amino acid sequence selected from SEQ ID NOs: 2 to 20, or a fragment thereof.

[0147] In further embodiments, the detection is by protein microarray, fluorescent detection, flow cytometry, microfluidic device, lateral flow assay, vertical flow assay, or immunoassay. In certain embodiments, the detection is by lateral flow assay. In further embodiments, the method also includes administering a treatment to the subject. In certain embodiments, the treatment is surgery, radiation, chemotherapy, targeted therapy, or immunotherapy. In one embodiment, the cervical cancer is stage I, stage II, stage III, or stage IV.

[0148] In one embodiment, the present invention provides a kit comprising a sample collection unit, a lateral flow device, and instructions for using the lateral flow device.

[0149] A sample collection device is any device that can be used to collect samples such as blood, plasma, urine, saliva, sweat, organ biopsies, cerebrospinal fluid (CSF), tears, vaginal fluid, feces, skin, and hair.

[0150] Lateral flow devices are easy-to-use diagnostic devices used to confirm the presence or absence of a target analyte (e.g., a pathogen or biomarker in a sample). The most commonly known type of lateral flow rapid test strip is the pregnancy test.

[0151] Typically, lateral flow assays use a device containing several pads (made of a series of capillary beds, capable of transporting fluids): a sample pad to receive the liquid sample, a positive control, a positive line, and a conjugate pad containing a reactive molecule used to visualize the test line.

[0152] For target protein detection, the conjugate pad contains an antibody specific to the target protein conjugated with a detectable tag, generating a positive line (positive control) containing an immobilized anti-anti-target protein antibody (e.g., an anti-IgG antibody) and a test line containing an immobilized anti-target protein antibody. When the sample pad is contacted with a sample containing the target protein, the target protein reacts with the anti-target protein antibody conjugated with a detectable tag in the conjugate pad. As fluid flows through the test and positive lines, the target protein present in the sample conjugated with a labeled antibody reacts with the immobilized anti-target protein antibody on the test line, and the anti-target protein antibody conjugated with a detectable tag but not conjugated to the target protein reacts with the immobilized anti-Ig antibody on the positive line. Both reactions generate a positive reading at the test and positive lines.

[0153] In one embodiment, the lateral flow device is configured to detect and / or label proteins selected from the group consisting of farnesyl pyrophosphate synthase, neurofibromin I, glyceraldehyde-3 phosphate dehydrogenase, fibronectin domain type III-containing protein 1, eukaryotic translation initiation factor 4A-I, L-lactate dehydrogenase B chain, heterogeneous nuclear ribonucleoprotein A1, polycystic kidney disease 1-like protein 1, heat shock protein cognate 71 kDa, ankyrin-3, Rho23 GTPase-activating protein, cytoskeletal keratin 78 type II, alpha-3 collagen chain(VI), beta subunit of proteasome type 5, heterogeneous nuclear ribonucleoprotein A2 / B1, and histone H2B. The assay detects at least one polypeptide selected from type 1-B, a homolog of DnaJ subfamily C member 13, β-enolase, glutathione S-transferase P, glutathione S-transferase Mu3, or a fragment thereof, or a polypeptide or fragment thereof having at least about 70% sequence identity to a polypeptide having an amino acid sequence selected from SEQ ID NOs: 1 to 147. In one embodiment, the at least one polypeptide is a polypeptide or fragment thereof having at least about 70% sequence identity to a polypeptide having an amino acid sequence selected from SEQ ID NOs: 1 to 20.

[0154] In additional embodiments, the at least one polypeptide is farnesyl pyrophosphate synthase or a fragment thereof, and at least one polypeptide selected from neurofibromin I, glyceraldehyde-3-phosphate dehydrogenase, fibronectin domain type III-containing protein 1, eukaryotic translation initiation factor 4A-I, L-lactate dehydrogenase B chain, heterogeneous nuclear ribonucleoprotein A1, polycystic kidney disease 1-like protein 1, heat shock protein cognate 71 kDa, ankyrin-3, Rho23 GTPase-activating protein, cytoskeletal keratin 78 type II, alpha-3 collagen chain (VI), beta subunit of proteasome type 5, heterogeneous nuclear ribonucleoprotein A2 / B1, histone H2B type 1-B, homolog of DnaJ subfamily C member 13, beta-enolase, glutathione S-transferase P, glutathione S-transferase Mu3, or a fragment thereof. In a further embodiment, the at least one polypeptide includes a polypeptide having at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO: 1, or a fragment thereof, and at least one polypeptide having at least about 70% sequence identity to a polypeptide having an amino acid sequence selected from SEQ ID NOs: 2-20, or a fragment thereof.

[0155] In another embodiment, the lateral flow device detects at least one polypeptide by immunoassay.In one embodiment, the sample collection unit collects a blood sample.

[0156] In a further aspect, the present invention provides the use of detection of at least one polypeptide for the diagnosis of cervical cancer in a subject in need thereof, said at least one polypeptide being farnesyl pyrophosphate synthase, neurofibromin I, glyceraldehyde-3-phosphate dehydrogenase, fibronectin domain type III-containing protein 1, eukaryotic translation initiation factor 4A-I, L-lactate dehydrogenase B chain, heterogeneous nuclear ribonucleoprotein A1, polycystic kidney disease 1-like protein 1, heat shock protein cognate 71 kDa, ankyrin-3, Rho23 GTPase-activating protein, cytoskeletal keratin 78 type II, alpha-3 collagen chain (VI), beta subunit of proteasome type 5, heterogeneous nuclear ribonucleoprotein A2 / B1, histone H2B. The at least one polypeptide is selected from the group consisting of type 1-B, a homolog of DnaJ subfamily C member 13, β-enolase, glutathione S-transferase P, glutathione S-transferase Mu3, or a fragment thereof, or a polypeptide or fragment thereof having at least about 70% sequence identity to a polypeptide having an amino acid sequence selected from SEQ ID NOs: 1 to 147. In one embodiment, the at least one polypeptide is a polypeptide or fragment thereof having at least about 70% sequence identity to a polypeptide having an amino acid sequence selected from SEQ ID NOs: 1 to 20.

[0157] In a further embodiment, the at least one polypeptide is detected in a sample from the subject, wherein the sample is a blood sample. In another embodiment, the at least one polypeptide is farnesyl pyrophosphate synthase or a fragment thereof, and at least one polypeptide selected from neurofibromin I, glyceraldehyde-3-phosphate dehydrogenase, fibronectin domain type III-containing protein 1, eukaryotic translation initiation factor 4A-I, L-lactate dehydrogenase B chain, heterogeneous nuclear ribonucleoprotein A1, polycystic kidney disease 1-like protein 1, heat shock protein cognate 71 kDa, ankyrin-3, Rho23 GTPase-activating protein, cytoskeletal keratin 78 type II, alpha-3 collagen chain (VI), beta subunit of proteasome type 5, heterogeneous nuclear ribonucleoprotein A2 / B1, histone H2B type 1-B, homolog of DnaJ subfamily C member 13, beta-enolase, glutathione S-transferase P, glutathione S-transferase Mu3, or a fragment thereof. In one embodiment, the at least one polypeptide is a polypeptide having at least about 70% sequence identity to a polypeptide having the amino acid sequence of SEQ ID NO: 1, or a fragment thereof, and at least one polypeptide having at least about 70% sequence identity to a polypeptide having an amino acid sequence selected from SEQ ID NOs: 2 to 20, or a fragment thereof.

[0158] In other embodiments, detection is by protein microarray, fluorescence detection, flow cytometry, a microfluidic device, a lateral flow assay, a vertical flow assay, or an immunoassay. In certain embodiments, detection is by a lateral flow assay.

[0159] The following examples are provided to further illustrate embodiments of the present invention, but are not intended to limit the scope of the invention. They are typical of those that might be used, but alternatively, other procedures, methods, or techniques known to those skilled in the art may be used. [Example]

[0160] Example 1 Secretome analysis of cervical cancer cell lines To identify cervical cancer biomarkers, we performed secretome analysis of cervical cancer cell lines HeLa (cervical adenocarcinoma, positive for HPV18), SiHa (grade II squamous cell cervical carcinoma, positive for HPV16), and C-33A (cervical carcinoma, negative for HPV), as well as the HaCaT cell line as a negative control. These lines were selected because they represent the most frequently occurring histological and viral genotypes in cervical intraepithelial lesions and cervical cancer (CC), and were cultured (in vitro secretome) or inoculated into mice (ex vivo secretome).

[0161] HeLa and SiHa cells were cultured in serum-free Advanced RPMI 1640 supplemented with 2 mM L-glutamine and 1% v / v penicillin-streptomycin at 37°C and 5% CO2 until they reached 70-80% confluence. The cells were washed three times with sterile physiological solution (0.9% NaCl (w / v)). As shown in Figure 2, on day 6, when the cells reached 70% confluence, there was no significant difference in proliferation between the cells.

[0162] For in vitro secretome analysis, the cells were then incubated in phenol red-free, serum-free RPMI 1640 (Gibco, Invitrogen) for 20 hours, and the medium was collected and centrifuged at 1,500 g for 5 minutes. The supernatant was passed through a 0.22 μm PVDF membrane (Millex, Millipore) and stored at −70°C until further use (see Figure 1).

[0163] For ex vivo secretome analysis, secreted proteins were analyzed using 10 7HeLa or SiHa cells were recovered from tumors harvested from inoculated female Nu / Nu mice (4–6 weeks old). At 30, 45, and 50 days after inoculation, tumors were harvested (triplicates), washed three times with 50 mL of physiological solution, and then incubated for 20 hours in phenol red-free, serum-free RMPI medium. The medium was removed and centrifuged at 1,500 × g for 5 minutes. The supernatant was passed through a 0.22 μm pore size PVDF membrane (Millex, Millipore) and stored at -70 °C until further use (see Figure 1). Secreted proteins recovered in vitro and ex vivo were lyophilized and resuspended in 1 mL of ultrapure water. Protein isolation was performed by phenol extraction.

[0164] To identify proteins secreted by different cell lines, proteins were separated by electrophoresis on an SDS-PAGE matrix and stained with bright Coomassie blue (see Figure 3A). Each lane containing 30 μg of protein was cut into 20 lines across the column, and the contained proteins were extracted and digested with trypsin. The generated peptides were analyzed using a nanoLC-MS / MS system (Q-TOF Synapt G2 MS; Waters). Peptide and protein identification was performed using the MASCOT search engine with the MASCOT Distiller interface (Matrix Science). The databases referenced were Swiss-Prot and NCBI.

[0165] We identified 1,662 secretome proteins (see Figure 3B). As shown in the Venn diagram in Figure 3C, the intersection between the shared proteins of the CC cell lines and their negative controls is shown. The three CC cell lines shared 20 proteins that were absent in the negative controls (see Table 3). These proteins were candidates for use in rapid diagnostic tests. In addition to qualitative studies, we performed quantitative analysis of the 200 secreted proteins using label-free quantification (LFQ) technology. As shown in Figure 4A, 92 proteins were found to be overexpressed in the three CC cell lines according to their Log2 values ​​(CC cell lines vs. HaCaT) (45 overexpressed proteins in HeLa, 35 overexpressed proteins in SiHa, and 12 overexpressed proteins in C-33A). As shown in Figure 4B, six secreted proteins: glyceraldehyde-3-phosphate dehydrogenase, cognate heat shock protein 71 kDa, L-lactate dehydrogenase B chain, β subunit of proteasome type 5, and heterogeneous nuclear ribonucleoprotein A2 / B1 were found to be expressed in the three CC cell lines compared to their negative controls. Furthermore, as shown in Figure 4C (representing a heat map of proteins expressed in the cell lines, complete concatenated hierarchical grouping indicates values ​​in Log2 (protein expression / HSP71) on the color scale), hierarchical analysis by clusters in the heat map revealed similarities in protein expression between HPV-positive cell lines (SiHa and HeLa). These analyses allowed us to obtain a set of commonly overexpressed proteins for HPV strains and CC strains.

[0166] [Table 3]

[0167] Example 2 Cervical tumor detection To assess whether the proteins identified in the in vitro secretome analysis could be used as biomarkers for the detection of cervical tumors, female mice were inoculated with DC cells to develop tumors, and secreted proteins were measured in the serum of the animals (see Figure 5A).

[0168] A cohort of nine mice was generated, and three different cell lines and their controls were established at three different times of PT (tumor progression). 7 Cells were inoculated with DC tumor cell lines (either HeLa or SiHa cells), and serum was collected 30, 45, and 50 days after inoculation. Serum was subjected to Western blot analysis using 20 μg of protein per sample. Tests were performed in triplicate and presented as mean values ​​(± standard deviation). Statistics were performed using Student's t-test.

[0169] As shown in Figure 5B, detection of one of the secretome proteins identified in Example 1 is illustrated. By Western blot, farnesyl pyrophosphate synthase protein was found to be detectable in the serum of mice inoculated with HeLa and SiHa (serum from uninoculated mice was used as a control). This protein was expressed in the serum of all tumor-bearing mice, and the level of expression was found to increase over time in the serum of mice inoculated with SiHa, as detailed in Figure 5C.

[0170] Further validation of the protein farnesyl pyrophosphate synthase as a serum biomarker was performed in serum obtained from CC patients as follows.

[0171] Sera from 10 patients with CC and 10 negative control patients with CC were tested, and the expression of farnesyl pyrophosphate synthase was assessed by Western blot. As shown in Figures 6A and 6B, all patients analyzed exhibited expression of farnesyl pyrophosphate synthase, whereas no expression was found in the serum of the controls. Expression levels were also observed to vary between patients (see Figure 6C). As further shown in Figures 7A-7C, ankyrin-3 was also expressed at significantly higher levels in patient serum compared to control serum, demonstrating its potential as a potential biomarker for detecting cervical cancer. Proteomic analysis of the secretome identified 20 proteins present in CC cells but absent in negative control serum. Of the six overexpressed proteins, farnesyl pyrophosphate synthase and ankyrin-3 were used as proof-of-principle to demonstrate that their levels of expression (i.e., overexpression) could be analyzed in patient serum, indicating that these proteins may be useful and promising candidates in identifying this disease.

[0172] Example 3 Detection of precancerous cervical lesions To evaluate whether proteins identified in the in vitro secretome analysis could be used as biomarkers to detect precancerous cervical lesions, sera from patients presenting with precancerous cervical lesions were evaluated for the detection of biomarkers by Western blot.

[0173] Sera from patients with cervical cancer or with preneoplastic lesions (controls) without lesions were collected and analyzed for expression of ankyrin-3, Rho23 GTPase-activating protein, α-3 collagen chain(IV), β-enolase, farnesyl pyrophosphate synthase, histone H2B type 1-BB, heterogeneous nuclear ribonucleoprotein A2 / B1, heat shock protein cognate 71 kDa, cytoskeletal keratin 78 type II, β-subunit of proteasome type 5, and homolog of DnaJ subfamily C member 13.

[0174] As shown in Figures 8A-8C, it was demonstrated that farnesyl pyrophosphate synthase was detectable in the serum of patients with precancerous cervical lesions L1 and L2 compared to control serum. Specifically, the expression of farnesyl pyrophosphate synthase was found to be 12-fold higher in the serum of patients with precancerous lesions compared to control serum (see Figure 8D). This demonstrates that precancerous lesions as well as cancerous lesions (see Example 2) can be detected in patient serum by detecting the expression of farnesyl pyrophosphate synthase in serum, and that farnesyl pyrophosphate synthase can be used as a biomarker for detecting precancerous cervical lesions.

[0175] As shown in Figures 9A-9C, ankyrin-3 was demonstrated to be detectable in the serum of patients with precancerous cervical lesions L1 and L2 compared to control serum. Specifically, ankyrin-3 expression in the serum of patients with precancerous lesions was found to be 10-fold higher than in controls (see Figure 9D). This indicates that precancerous lesions, as well as cancerous lesions (see Example 2), can be detected in patient serum by detecting ankyrin-3 expression in serum, and that ankyrin-3 can be used as a biomarker for detecting precancerous cervical lesions.

[0176] Similar results were obtained when protein quantification was intended by ELISA rather than Western blot.

[0177] Example 4 Lateral flow assay for the detection of cervical neoplasia and precancerous lesions For the lateral flow assay, strips containing test line and dried spot antibodies for the positive line were prepared, and samples taken from patients were tested for the detection of farnesyl pyrophosphate synthase.

[0178] Blood samples collected from patients were either diluted directly into chase buffer at a dilution ratio of 1 / 5 (for serum samples) or diluted into chase buffer after further absorption onto a blood separator pad (for whole blood samples). 70 ul of diluted sample was used for each test.

[0179] The strips were assembled by removing the membrane portion of the protective cover and applying a CN-95 membrane. The two protective covers were removed from the above-mentioned sections where the nitrocellulose was placed. A 21 mm wick pad was then applied by aligning the top of the wick pad with the top edge of the backing card, and the excess backing card below the membrane was trimmed away, leaving only the membrane and wick pad. The strips were cut to 5.0 mm width using a kinematic guillotine and packaged in pouches with desiccant.

[0180] Test and positive lines were then prepared on the strips by spotting and drying the antibody. On 20 cut test strips, 1.0 μL of test line antibody was applied approximately 9 mm from the bottom of the nitrocellulose, and on each cut spotted test strip, 1 μL of control line antibody was applied approximately 15 mm from the bottom of the nitrocellulose. The strips were tapped on paper and placed in a 40°C oven for 1 hour. Once dry, the strips were packaged with desiccant. The antibody was either pre-conjugated with gold (colloidal gold was used) or biotinylated.

[0181] For the assay, each conjugate was diluted to 0.02% solids using 50 mM boric acid, 0.5% casein, and 1% Tween. 8 μL of conjugate, followed by 10 μL of serum, was pipetted into a glass tube. Half of the strip was placed in the glass tube, the bottom of the nitrocellulose was immersed in the test solution, and the conjugate / serum solution was run up the strip. Subsequently, 50 μL of 1× PBS, 1% Tween 20 was added to the glass tube to chase the sample.

[0182] Using the FLI assay described herein, it has been demonstrated that expression levels of farnesyl pyrophosphate synthase can be determined in liquid samples (such as serum) taken from patients, thus enabling low- and high-grade precancerous lesions as well as cancerous cervical lesions to be detected using the device.

[0183] Although the invention has been described with reference to the above examples, it will be understood that modifications and variations are encompassed within the spirit and scope of the invention. Accordingly, the invention is limited only by the following claims.

Claims

1. The following steps: (a) detecting at least one polypeptide in a sample from a subject, wherein the at least one polypeptide is a secreted polypeptide selected from the group consisting of heterogeneous nuclear ribonucleoprotein A1, eukaryotic translation initiation factor 4A-I, neurofibromin I, glutathione S-transferase Mu3, ankyrin-3, fibronectin domain type III-containing protein 1, L-lactate dehydrogenase B chain, polycystic kidney disease 1-like protein 1, heat shock protein cognate 71 kDa, Rho23 GTPase-activating protein, cytoskeletal keratin 78 type II, alpha-3 collagen chain (VI), beta subunit of proteasome type 5, heterogeneous nuclear ribonucleoprotein A2 / B1, histone H2B type 1-B, homolog of DnaJ subfamily C member 13, beta-enolase, and glutathione S-transferase P; and (b) comparing said detection of said at least one polypeptide to a control level.

1. An in vitro method for detecting cervical cancer or a precancerous lesion of cervical cancer in a sample, comprising:

2. 1. An in vitro method for detecting cervical cancer or a precancerous lesion of cervical cancer in a sample, comprising: (a) detecting at least one polypeptide in a sample from a subject, wherein the at least one polypeptide is a secreted polypeptide selected from the group consisting of heterogeneous nuclear ribonucleoprotein A1, eukaryotic translation initiation factor 4A-I, neurofibromin I, glutathione S-transferase Mu3, ankyrin-3, fibronectin domain type III-containing protein 1, L-lactate dehydrogenase B chain, polycystic kidney disease 1-like protein 1, heat shock protein cognate 71 kDa, Rho23 GTPase-activating protein, cytoskeletal keratin 78 type II, alpha-3 collagen chain (VI), beta subunit of proteasome type 5, heterogeneous nuclear ribonucleoprotein A2 / B1, histone H2B type 1-B, homolog of DnaJ subfamily C member 13, beta-enolase, and glutathione S-transferase P; and (b) comparing said detection of said at least one polypeptide with a control level, wherein a measured value of said at least one polypeptide higher than the control level indicates cervical cancer or a precancerous lesion of cervical cancer. wherein the sample is selected from the group consisting of blood, plasma, urine, saliva, tears, and vaginal fluid.

3. 3. The method of claim 1 or 2, wherein the detecting step is by protein microarray, fluorescence detection, flow cytometry, a microfluidic device, a lateral flow assay, vertical flow, or an immunoassay.

4. 1. An in vitro method for predicting response to treatment of a subject having cervical cancer or a precancerous lesion of cervical cancer, comprising the steps of: (a) detecting at least one polypeptide in a sample from a subject, wherein the at least one polypeptide is a secreted polypeptide selected from the group consisting of heterogeneous nuclear ribonucleoprotein A1, eukaryotic translation initiation factor 4A-I, neurofibromin I, glutathione S-transferase Mu3, ankyrin-3, fibronectin domain type III-containing protein 1, L-lactate dehydrogenase B chain, polycystic kidney disease 1-like protein 1, heat shock protein cognate 71 kDa, Rho23 GTPase-activating protein, cytoskeletal keratin 78 type II, alpha-3 collagen chain (VI), beta subunit of proteasome type 5, heterogeneous nuclear ribonucleoprotein A2 / B1, histone H2B type 1-B, homolog of DnaJ subfamily C member 13, beta-enolase, and glutathione S-transferase P; and (b) predicting a response to treatment based on said detection of said at least one polypeptide by comparing said detection of said at least one polypeptide with a control level. wherein the sample is selected from the group consisting of blood, plasma, urine, saliva, tears, and vaginal fluid.

5. 5. The method of claim 4, wherein the detecting step is by protein microarray, fluorescent detection, flow cytometry, a microfluidic device, a lateral flow assay, a vertical flow assay, or an immunoassay.

6. 6. The method of claim 4 or 5, wherein the treatment is selected from the group consisting of surgery, radiation, chemotherapy, targeted therapy, and immunotherapy.

7. 1. An in vitro method for determining the stage of cervical cancer in a subject in need thereof, comprising the steps of: (a) detecting at least one polypeptide in a sample from a subject, wherein the at least one polypeptide is a secreted polypeptide selected from the group consisting of heterogeneous nuclear ribonucleoprotein A1, eukaryotic translation initiation factor 4A-I, neurofibromin I, glutathione S-transferase Mu3, ankyrin-3, fibronectin domain type III-containing protein 1, L-lactate dehydrogenase B chain, polycystic kidney disease 1-like protein 1, heat shock protein cognate 71 kDa, Rho23 GTPase-activating protein, cytoskeletal keratin 78 type II, alpha-3 collagen chain (VI), beta subunit of proteasome type 5, heterogeneous nuclear ribonucleoprotein A2 / B1, histone H2B type 1-B, homolog of DnaJ subfamily C member 13, beta-enolase, and glutathione S-transferase P; and (b) determining the stage of cervical cancer in said subject based on said detection of said at least one polypeptide. wherein the sample is selected from the group consisting of blood, plasma, urine, saliva, tears, and vaginal fluid.

8. 8. The method of claim 7, wherein the detecting step is by protein microarray, fluorescent detection, flow cytometry, a microfluidic device, a lateral flow assay, a vertical flow assay, or an immunoassay.

9. (a) a sample collection unit; (b) antibody detection-based devices; (c) instructions for using said antibody detection-based device; and A kit for detecting cervical cancer or a precancerous lesion of cervical cancer in a sample, comprising:

10. The kit of claim 9, wherein the antibody-detection-based device detects at least one polypeptide, wherein the at least one polypeptide is a secreted polypeptide selected from the group consisting of heterogeneous nuclear ribonucleoprotein A1, eukaryotic translation initiation factor 4A-I, neurofibromin I, glutathione S-transferase Mu3, ankyrin-3, fibronectin domain type III-containing protein 1, L-lactate dehydrogenase B chain, polycystic kidney disease 1-like protein 1, heat shock protein cognate 71 kDa, Rho23 GTPase-activating protein, cytoskeletal keratin 78 type II, alpha-3 collagen chain (VI), beta subunit of proteasome type 5, heterogeneous nuclear ribonucleoprotein A2 / B1, histone H2B type 1-B, a homolog of DnaJ subfamily C member 13, beta-enolase, and glutathione S-transferase P; and the sample is selected from the group consisting of blood, plasma, urine, saliva, tears, and vaginal fluid.

10. The kit of claim 9 , wherein the sample collection unit collects a blood sample.

11. The kit of claim 9 , wherein the antibody detection-based device is a lateral flow device.

12. The kit of claim 9, wherein the antibody detection-based device is capable of performing multiplex assays.

Images